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Abstract
Reperfusion therapy is the indispensable treatment of acute myocardial infarction (AMI) and must be applied as
soon as possible to attenuate the ischemic insult. However, reperfusion is responsible for additional myocardial
damage likely involving opening of the mitochondrial permeability transition pore (mPTP). A great part of
reperfusion injury occurs during the first minute of reperfusion. The prolonged opening of mPTP is considered
one of the endpoints of the cascade to myocardial damage, causing loss of cardiomyocyte function and viability.
Opening of mPTP and the consequent oxidative stress due to reactive oxygen and nitrogen species (ROS/RNS)
are considered among the major mechanisms of mitochondrial and myocardial dysfunction. Kinases and mi-
tochondrial components constitute an intricate network of signaling molecules and mitochondrial proteins,
which interact in response to stressors. Cardioprotective pathways are activated by stimuli such as pre-
conditioning and postconditioning (PostC), obtained with brief intermittent ischemia or with pharmacological
agents, which drastically reduce the lethal ischemia/reperfusion injury. The protective pathways converging on
mitochondria may preserve their function. Protection involves kinases, adenosine triphosphate-dependent po-
tassium channels, ROS signaling, and the mPTP modulation. Some clinical studies using ischemic PostC during
angioplasty support its protective effects, and an interesting alternative is pharmacological PostC. In fact, the
mPTP desensitizer, cyclosporine A, has been shown to induce appreciable protections in AMI patients. Several
factors and comorbidities that might interfere with cardioprotective signaling are considered. Hence, treatments
adapted to the characteristics of the patient (i.e., phenotype oriented) might be feasible in the future. Antioxid.
Redox Signal. 00, 000–000.
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I. Introduction
This review describes the role of mitochondria in thecardioprotection by preconditioning (PreC) and post-
conditioning (PostC): two cardioprotective maneuvers that
target mitochondria. Before providing details on the condi-
tionings, we briefly introduce the ischemia/reperfusion (I/R)
injury, the cardioprotective strategies, and their molecular
pathways. Moreover, we describe in the details some factors
involved in the cross-talk between the cytosol and mito-
chondria (mitochondrial network) in different scenarios, in-
cluding I/R and cardioprotection. Besides the classic players
(protein kinase C [PKC], glycogen synthase kinase-3b [GSK-
3b], mitochondrial ATP-sensible K + [mKATP] channels, etc.),
we also describe the role of relatively new cardioprotective
mitochondrial factors such as signal transducer and activator
of transcription-3 (STAT-3) and Pim-1. Among important el-
ements of the cross-talk between elements of the mitochon-
drial network, we consider reactive oxygen and nitrogen
species (ROS/RNS), which are mainly produced by mito-
chondria. Then, we describe how the considered elements
come into play together with other factors in the I/R scenario,
in the regulation of mitochondrial function, and in the cardi-
oprotective pathways that converge on mitochondria. The
main protective pathways considered are the so-called re-
perfusion injury salvage kinases (RISKs) and survivor acti-
vating factor enhancement (SAFE). Sincemitochondria are the
main source of ROS in the cardiomyocytes, emphasis is given
to ROS signaling in cardioprotection. We also briefly consider
the role of mitochondria in autophagy (a tightly regulated
cellular housekeeping process that may confer increased re-
sistance to I/R injury) and in the so-called second window of
protection (SWOP) induced by PreC. Before taking into ac-
count the clinical translation of conditioning strategies, we
discuss the role of aging and some comorbidities, which
modify the mitochondrial function and the cardioprotective
outcome. In considering transition to clinic, possible pitfalls of
ischemic PostC and possible aspects that should be consid-
ered for a successful cardioprotective approach in early re-
perfusion with pharmacological PostC are discussed.
A. Acute myocardial infarction and reperfusion injury
Acute myocardial infarction (AMI) continues to be a major
cause of morbidity and mortality, and infarct size is the major
determinant of patients’ prognosis. Millions of people world-
wide each year die from AMI. With the in-hospital mortality
rate of 5%–6% among ST segment elevation myocardial in-
farction (STEMI) patients and about 4% among non-ST segment
elevation myocardial infarction (NSTEMI) patients, AMI re-
mains the first cause of death in Western countries and is the
leading cause of chronic heart failure and cardiovascular dis-
eases (302). All this happens despite the incredible improve-
ments in the care of patients with AMI in recent years. In fact,
promptmyocardial ischemic reperfusion is a very good strategy
to reduce the infarct size and reduce all manifestations of
postischemic injury resulting in improvedoutcomes.The culprit
coronary artery can be opened by percutaneous coronary in-
tervention (PCI) or fibrinolytic agents, with or without stenting.
Although early reperfusion is the only way to save an ischemic
organ, reversible and irreversible organ damage occurs during
the early moments of reperfusion (that is reperfusion injury).
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Myocardial ischemia is characterized by severe hypoxia,
acidosis, energy depletion, and ion homeostasis alterations
leading to cardiac dysfunction and, ultimately, to cell death.
Mitochondria are abundant in cardiomyocytes, and they use
oxygen as the principal substrate, so that it is not surprising
that they play a role of protagonist in the I/R scenario during
hypoxia/ischemia/reoxygenation. Mitochondria also play a
pivotal role in ion homeostasis. In fact, the key events that
occur in cardiomyocytes during I/R are imbalanced and al-
tered exchange of ions. These are precipitated by the meta-
bolic and chemical changes of ischemia, which then triggers
mitochondrial dysfunction during reperfusion. Therefore,
mitochondria play a critical role in the regulation of cardiac
function in both health and disease, and are also increasingly
recognized as end effectors for various cardioprotective sig-
naling pathways. Therefore, understanding the role of mito-
chondria in this scenario is a requisite to find an appropriate
therapeutic approach.
Myocardial injury that follows ischemia and reperfusion is,
of course, related to the duration of ischemia. Successful re-
perfusion has been shown to dramatically reduce the infarct
size; the sooner it is performed, the greater the amount of
saved myocardium. However, it has also been seen that a
large component of the damage takes place during the first
minutes of reperfusion when an amplification of ischemic
injury or additional damage occurs (12, 115, 116, 256, 396).
Intracellular Ca2 + overload, inadequate resynthesis of aden-
osine triphosphate (ATP), oxidative stress by ROS, and loss of
membrane phospholipids have been suggested as contribut-
ing to reperfusion injury (21, 285, 383). Therefore, both is-
chemia and reperfusion contribute to organ damage.
Reperfusion injury includes arrhythmias, transient mechani-
cal dysfunction of the heart or myocardial stunning, micro-
vascular damage, and no reflow, as well as inflammatory
responses. In reperfusion, cell death can occur by apoptosis,
necrosis, and autophagy [the reader is redirected to extensive
review on this topic (e.g., 115, 260, 269, 270, 290, 347, and 369)].
However, in contrast to necrosis and apoptosis, which inevi-
tably lead to cell death, autophagy is not simply a destructive
phenomenon, but under certain conditions, autophagy can be
considered a protective mechanism against I/R injury (290,
347). The vulnerability to I/R injury is likely to be heavily
influenced by the autophagic control of protein and organelle
quality, including mitochondria. For these reasons, autop-
hagy is briefly discussed in a dedicated section of this review
(see section IX).
A relevant role in exacerbating myocardial injury by fa-
voring mitochondrial permeability transition pore (mPTP)
opening is played by ROS, which are generated at various
sites in the cell and within mitochondria. The control of mPTP
opening and ROS generation appears to modulate the I/R
injury. To control mitochondrial function, a plethora of reac-
tions occurs outside and within the mitochondria themselves.
In Figure 1 are reported some of the elements in play, which
will be responsible for cell death via mPTP opening: Figure 1A
displays the balance of factors controlling mPTP opening in
ischemia; Figure 1B illustrates the conditions favoring the
mPTP opening and the main consequences upon reperfusion.
B. Strategies to reduce injury
Since recent data indicate that different forms of cell
death are probably correlated (115, 116), the best strategy for
developing cardioprotective agents is not to define the mode
of cell death and its proportion occurring during I/R, but to
identify mediators active in all forms of cell death. In this
context, mitochondria have emerged as the relevant targets.
Interestingly, the change in the mitochondrial membrane
permeability occurring in early reperfusion appears to be
among the most important regulators of all forms of cell
death.
The timing of the reperfusion injury occurrence explains
the efficacy of the PostC interventions in limiting the infarct
size and in ameliorating the mechanical recovery of the heart
(174, 329). The involved factors and the consequences of PostC
are discussed in the following sections. Timing of cardiopro-
tective interventions is of paramount importance for limiting
mPTP opening. In fact, both ischemic PreC and ischemic
FIG. 1. Schematic representation of fac-
tors controlling mitochondrial permeability
transition pore (mPTP) open probability,
during ischemia (A) and during reperfusion
(B). Ischemia-induced intracellular acidosis
may shift the equilibrium toward the closed
state. Upon reperfusion, the recovery of pH
toward neutral values facilitates the con-
comitant elevation of matrix [Ca2 + ] and re-
active oxygen and nitrogen species (ROS/
RNS) formation in promoting mPTP open-
ing. For other acronyms, see the list of Ab-
breviations Used.
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PostC have been demonstrated to significantly attenuate I/R
injury. Although PreC can be obtained with one or more brief
coronary occlusions (a few min each) before the infarcting
ischemia, PostC may be performed with one or more brief
occlusions (a few seconds each), starting immediately after the
end of the ischemia in animals and humans (e.g., 61, 133–136,
174, 260, 329, and 333). Moreover, PreC initiates an immediate
protective response (early PreC) and 12–24 h later, a more
modest protection against the infarct size (SWOP), which will
be considered briefly in the section VIII (Fig. 2).
The necessity of the early intervention for PostC to be
protective has emphasized the importance of reperfusion in
inducing I/R injury. Since the PostC maneuvers are not pro-
tective if they are carried out after the first minutes of re-
perfusion (260, 392), this period seems to be confirmed as the
interval when most damage takes place. The main advantage
of PostC with regard to PreC consists in the more frequent
possibility of clinical application. In fact, due to the unpre-
dictability of an ischemic event, PostC can be utilized with
reperfusion procedures, which may be under the control of
physicians (212, 333).
Cardioprotection may be due to passive mechanisms,
which are responsible for a reduction in the reperfused heart
of (i) endothelial cell activation and dysfunction; (ii) neutro-
phil activation and accumulation; (iii) tissue ROS generation;
and (iv)microvascular injury and tissue edema (269, 368, 369).
However, cardioprotection by PreC and PostC triggers also
active mechanisms, which consist of the activation of intra-
cellular signaling pathways that lead to limitation of cell death
(268, 269, 369, 393). These signaling pathways initiate before
sustained ischemia for ischemic PreC, but importantly, they
initiate also at the very start of reperfusion for both PreC and
PostC. In fact, both ischemic PreC and PostC reduce myo-
cardial damages due to ischemia and reperfusion.
While in ischemic PreC, the brief cycles of protective I/R
are employed before the sustained infarcting ischemia;
in ischemic PostC, they are employed at the onset of re-
perfusion after sustained ischemia; however, both ischemic
PreC and PostC are protective phenomena both targeting
reperfusion (Fig. 3); as such, they share certain signaling
elements in experimental analyses (137, 144, 145, 269, 382).
At reperfusion, there are three populations of cells: (i) those
that were killed by sustained ischemia, (ii) those that had
sublethal injury and will survive, and (iii) those that are
alive, but will die mainly from mPTP opening. Both PreC
and PostC target this last group of cells. In fact, it is now
thought that the actual PreC protection occurs in the re-
perfusion, rather than the ischemic phase, and repopulation
of membrane receptors and activation of multiple kinases
are critical events (61, 64). In PreC, we recognize a trigger
phase in which adenosine, bradykinin, opioids, and possi-
bly, other surface receptors couple through multiple path-
ways to activate mKATP and PKC. In the ischemic phase,
PKC may act as a memory, and in reperfusion phase, signal
transduction pathways act to prevent mPTP opening (Fig.
3A). Also, PostC protects because it maintains acidosis
during early reoxygenation (167), which inhibits mPTP for-
mation and allows ROS signaling (Fig. 3B) that gives the
heart enough time to activate signaling pathways, and thus
to precondition itself against reperfusion injury.
The signaling elements recruited by these cardioprotective
phenomena, especially those of the PreC trigger phase, have
been extensively studied. It has become clear that different
pathways finally target the mitochondria, and that preserva-
tion of mitochondrial structure and function is central for
cardioprotection [for reviews see (27, 81, 260)]. In other words,
the mitochondrial structure and function are preserved by the
cardioprotective maneuvers, because they are able to affect
the cross-talk between cytosolic and mitochondrial ele-
ments. Besides the survival kinases of the RISK (Akt/ERK1/
2/GSK-3b) and protein kinase G (PKG)/PKC pathways,
also SAFE (TNF-a/JAK/STAT-3) pathways, as well as the
AMP-activated protein kinase (AMPK), Pim-1, and B-cell
lymphoma-2 (Bcl-2) family may contribute to preserve the
mitochondrial function and to avoid cell death.
Actually, the majority of the mitochondrial proteins is
synthesized in the cytosol and has to be imported (52, 100).
This import is influenced by protective maneuvers. Also,
mitochondrial factors/products (e.g., ATP, cytochrome c [Cyt
c], and ROS, mainly hydrogen peroxide [H2O2]) may be re-
leased in to the cytosol, affecting cell life and death. Both the
import toward and the release from mitochondria are influ-
enced by stressors like I/R and by cardioprotective maneu-
vers like PreC and PostC (e.g., 27, 137, and 139). Several of the
aforementioned signaling and mitochondrial components
take part to this cross-talk between the cytosol and mito-
chondria, constituting amitochondrial network. Here, wewill
FIG. 2. Schematic diagrams illustrating the protocols of
preconditioning (PreC) and postconditioning (PostC). PreC
is triggered by short periods of ischemia (a few minutes)
applied before the onset of a sustained period of ischemia.
PreC consists of two chronologically and pathophysiologi-
cally distinct phases: an early phase (Early PreC), which
develops very quickly, within a few minutes from the ex-
posure to the stimulus, but lasts only 1–2 h [this is the phe-
nomenon originally described by Murry et al. (239)], and a
late phase (Late PreC), that is the so-called second window of
protection (SWOP), which develops more slowly (requiring
6–12 h), but lasts much longer (3–4 days) (35, 37, 342, 348).
PostC is triggered by short periods of ischemia (a few sec-
onds) applied immediately after the end of the sustained
ischemia [this is the phenomenon originally described by
Zhao et al. (393)]. PostC maneuvers are not protective if they
are carried out after the first minutes of reperfusion (260,
392). For other acronyms, see the list of Abbreviations Used.
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consider some of these elements, which are modified by I/R
and cardioprotective maneuvers.
II. Mitochondrial Network
Due to space constraint, here, we consider only the
most frequently studied elements of the complex network of
signaling molecules between the cytosol and mitochondria
(Fig. 4).
A. Important kinases of the mitochondrial network
involved in I/R injury and cardioprotection
The heart should constantly adjust energy production to
energy supply and utilization, and is a high-energy consumer.
For this reason, the heart greatly depends on oxidative me-
tabolism for adequate energy production and on efficient
energy-transfer systems. Therefore, the function of mito-
chondria is finely regulated by intrinsic (e.g., mPTPs and
mKATP channels) and extrinsic factors (e.g., GSK-3b and PKC).
Before taking into account the role of mitochondria in the
scenario of I/R, it is useful to consider how some of these
factors are involved in the regulation of mitochondrial func-
tions in physiological conditions and during stress.
1. GSK-3b in cell survival. GSK-3b is important for gly-
cogen metabolism, but it is also involved in gene expression,
and cell survival. For instance, GSK-3b phosphorylates py-
ruvate dehydrogenase (PDH), creating an energy deficit in the
cell (158), and it also phosphorylates the docking site of
hexokinases (HKs) to voltage-dependent anion channel
(VDAC), facilitating the induction of outer mitochondrial
membrane (OMM) permeabilization and subsequent cell
death (50). The GSK-3b level may change in models of hy-
pertrophy (279), and its activity is mainly regulated via
phosphorylation: the phosphorylation of GSK-3b at serine 9
renders the protein inactive.
Pharmacological inhibition of GSK-3b (i.e., GSK-3b phos-
phorylation) either before ischemia or at reperfusion may re-
duce I/R injury. In fact, it seems that both ischemic PreC and
PostC are associated with enhanced GSK-3b phosphoryla-
tion/inhibition in rodent hearts (117, 236, 274, 356).
In the context of cardioprotection, it has been proposed that
activation of both the phosphatidylinositol 3-kinase (PI3K)/
protein kinase B (PKB or Akt) and the extracellular signal-
regulated kinase (ERK) 1/2 projects onto downstream ki-
nases, including GSK-3b, and ultimately to the OMM to affect
cellular survival (133, 134, 137). In fact, pharmacological in-
hibition of GSK-3b phosphorylation clearly abolishes cardio-
protection (185, 186). However, transgenic approaches have
revealed ambiguous results not only for GSK-3b but also for
GSK-3a; in fact,
(i) in transgenic mice in which serine 9 is replaced by al-
anine to render GSK-3b insensitive to phosphorylation,
infarct size reduction by ischemic PostC is lost (117);
(ii) in mice with a targeted knocking of noninhibitable
GSK-3a and GSK-3b, infarct size reduction by ischemic
PreC or PostC is preserved (248);
(iii) in knockout (KO) mice for GSK-3a, apoptotic cells in
the border zone of the infarction were increased,
suggesting that the a-isoform acts to limit ischemic
injury (210);
(iv) using RNA interference in neonatal rat cardiomyo-
cytes, it was concluded that the knockdown of GSK-
3b was protective against ischemic injury, but that the
knockdown of GSK-3a was not (185).
These apparently contradictory findings may be related to
different genetic strains and models. However, also PostC in
FIG. 3. Current theory for
PreC (A) and for PostC (B).
In the PreC, we recognize a
Trigger phase: adenosine
(Ade), bradykinin (BK), and
other surface receptors cou-
ple through multiple path-
ways to activate PKC and
possibly other kinases; ische-
mic phase (sustained ische-
mia): kinases act as a
memory; reperfusion phase
(early reperfusion): signal
transduction pathways act to
prevent mPTP opening. In
the PostC, intermittent PostC
ischemias do not allow a ra-
pid recovery of pH in early
reperfusion, thus keeping
mPTP closed and allowing
the heart to precondition it-
self. It has been suggested
that low pH in early re-
perfusion plays a role also in
PreC (139). For other acro-
nyms, see the list of Ab-
breviations Used.
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pigs did not increase postischemic GSK-3b phosphorylation
over that induced by reperfusion (328). Overall, these studies
support a highly variable role of both GSK-3a and GSK-3b for
cardioprotection.
Further studies are necessary to understand the conditions
affecting its protective role. Nevertheless, when protective,
the effects of GSK-3b involve mitochondrial proteins and
structures, for example, inhibition of mPTP opening and
control of mitochondrial adenine nucleotide transporter
(ANT) in the inner mitochondrial membrane (IMM) through
the OMM (117, 186, 246, 247). Since GSK-3b is mainly local-
ized in the cytosol, but targets mitochondrial proteins, atten-
tion has been directed to the presence and action of GSK-3b
within mitochondria. Increases in the content of total and
phosphorylated GSK-3b in mitochondria of isolated rat hearts
subjected to I/R and an enhancement of protein–protein in-
teraction between GSK-3b and VDAC or ANT have been
observed (239). At present, it is not at all clear how proteins
residing in the IMM (e.g., ANT and PDH), or even in the
matrix as in the case of cyclophilin D (Cyp-D) in cancer cells
(299), can be targeted andmodulated by this cytosolic protein
kinase. Nevertheless, phosphorylated GSK-3b inhibits mPTP
opening likely by multiple mechanisms, including preserva-
tion of HK in themPTP complex and prevention of interaction
of Cyp-D with ANT (50, 137).
In mitochondria, isolated from rat cardiomyocytes, the
phospho-GSK-3b-to-total GSK-3b ratio correlates with the
Ca2 + concentration needed to induce mPTP opening (231). It
has been, thus, suggested that the level of mitochondrial GSK-
3b phosphorylation at reperfusion is a determinant of the
threshold for mPTP opening (231). Accordingly, cardiopro-
tection by ischemic PostC was associated with enhanced mi-
tochondrial contents of total and phosphorylated GSK-3b and
with an increased phospho-/total GSK-3b ratio in ex vivo rat
hearts (274). However, translocation/phosphorylation of
GSK-3b to/in mitochondria was not affected by ischemic
PreC in isolated rat hearts (59).
In summary, it seems that in ischemic PreC and PostC, the
obligatory role of GSK-3b for cardioprotection is still contro-
versial and possibly species specific (117, 153, 185, 248, 328,
371, 382). Nevertheless, further studies are needed to specifi-
cally characterize the role of mitochondrial GSK-3b in cardi-
oprotection and to distinguish between the effects of cytosolic
and mitochondrial GSK-3b.
2. PKC family in the I/R scenario and cardioprotection.
The serine/threonine PKC family was first identified as in-
tracellular receptors for the tumor-promoting agents phorbol
esters. There are multiple isoforms of PKC that function in a
wide variety of biological systems. The conventional PKC
isoforms (PKC-a, b1, b2, and c) are activated by phosphati-
dylserine (PS), calcium, and diacylglycerol (DAG), or phorbol
esters such as phorbol 12-myristate 13-acetate (PMA),
whereas novel PKCs (PKC-d, e, h, and g) are activated by PS,
DAG, or PMA, but not by calcium. The atypical PKCs (PKC-f
and i/k) are not activated by calcium, DAG, or PMA; PKCk is
for mouse; the human homolog is termed PKCi.
Cardioprotective mechanisms involve the activation of
several membrane receptors of agonists such as adenosine,
bradykinin, and opioids. All these agonists eventually target
PKC: adenosine through the activation of phospholipase C,
and the other agonists through a more complex pathway that
includes serial activation of PI3K/Akt, nitric oxide synthase
(NOS), guanylyl cyclase, PKG, and opening of mKATP chan-
nels, and finally production and release of ROS, which target
PKC within and outside mitochondria (66, 67, 113, 296). Mi-
tochondrial ROS are represented by superoxide anion (O2
- )
fromwhich can derive its productsH2O2 and hydroxyl radical
(OH). Actually, H2O2 might be the only oxidant released
from mitochondria to the cytosol in physiological conditions;
the negatively charged O2
-  does not permeate the lipid bi-
layer of biological membranes. However, it is able to pass
through the pore of anion channels (Fig. 5), and in some cases,
it may play a role as such or after a reaction with nitric oxide
(NO) to form peroxynitrite (ONOO - ) (8, 9, 79, 81, 205, 399).
The PKC isoforms mainly studied in I/R and cardiopro-
tection are PKCa, PKCd, and PKCe. After I/R, PKCd enhances
and PKCe reduces irreversible myocardial injury in rodents.
FIG. 4. Elements of the mitochondrial network. Among
cytosolic and mitochondrial elements, exists a very complex
network of interactions. The interactions of this network are
better disentangled in the other figures. The double arrows
do not indicate direct interaction among elements, but indi-
cate that there is a cross-talk among the various elements. It
is likely that Akt can modulate almost all the downstream
elements. It is also likely that some of the elements and ki-
nases migrate from outside to inside the mitochondria. As
discussed in the text, most of the information relative to in-
terplay of this network derives from our laboratory and the
laboratories of J. Vinten-Johansen, D. Hausenloy & D. Yellon,
G. Heusch & R. Schulz, D. Garcia-Dorado, M. Choen & J.M.
Downey, and E. Murphy & C. Steenbergen, and from F. Di
Lisa and A. Halestrap’s laboratories. In particular, the in-
terconnections between elements, as for example, PKC and
PKG role, are matter of debate among some of these labo-
ratories. We will focus on the more common interrelations of
these elements in ischemia/reperfusion and cardioprotection
scenarios. ROS and RNS are second messengers of life or
death that may be produced by mitochondria (see text for
further explanation). Of course, each of the considered ele-
ments has multiple targets that are not considered in this
figure and in the text. For other acronyms, see the list of
Abbreviations Used.
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PKCa is the isoform involved in I/R injury and protection
from it in pigs (328).
Activation of PKCd induces cell death (apoptosis and onco-
sis) through the regulation of mitochondrial function. It has
been suggested that increased levels and catalytic activity of
PKCd in the mitochondrial fraction are associated with hyper-
phosphorylation of PDH (58). This and other mechanisms may
be involved in PKCd-induced cell death, whereas its degrada-
tion has been involved in protective mechanisms (55, 57).
Activation of PKCe protects mitochondrial function and
diminishes cell death. Upon a PreC stimulus, PKCe translo-
cates from the cytosol to the particulate fraction, but also to
themitochondria (251). Also, the cardioprotection by ischemic
PostC was lost in isolated rat hearts treated with aspecific and
specific PKCe inhibitors (276, 388).
Importantly, as said, PKCe may be activated by ROS sig-
naling (260, 288, 341).Withinmitochondria, PKCe is located in
the intermembrane space, and it is associated with the IMM,
but the presence of a second PKCe pool within the matrix has
been suggested (66). PKCe is imported into mitochondria by
heat shock protein 90 (Hsp90) and outer membrane translo-
case 20 (Tom20), playing a role in cardioprotection from I/R
injury (42). Within mitochondria, PKCe has several targets,
including mKATP channels and aldehyde dehydrogenase
(ALDH). The latter contributes to cardioprotection by inhi-
bition of toxic aldehyde formation (56). It has been reported
that PKCe phosphorylates VDAC when HKs (I and II) are
overexpressed. In fact, HKs play a pivotal role in promoting
cell survival by binding specifically to the VDAC, whereas
HK removal triggers cell death (50). PKCe also targets mito-
gen-activated protein kinases (MAPKs) and ERK, forming a
module that induces the phosphorylation and inactivation of
the pro-apoptotic protein Bad (9).
In summary, PKCs are important for the I/R and for the
cardioprotection by ischemic PreC and PostC. In particular,
mitochondrial PKCe contributes to cardioprotection by reg-
ulating the activity of several mitochondrial proteins (e.g.,
VDAC, connexin-43 [Cx43], mKATP channels, andALDH). On
the contrary, PKCd may play a pivotal role in I/R injury.
3. The role of STAT-3 in cardioprotection by PreC
and PostC. The STAT family consists of seven identified
FIG. 5. ROS/RNS are products of multiple enzymes and reactions within and outside the mitochondria. The immediate
product of multiple enzymes, including the enzymes of mitochondrial oxidative phosphorylation, may be the superoxide
anion (O2
- ), mainly generated at complexes I and III of the electron transport chain (ETC); however, due to spontaneous and
enzymatic formation by p66Shc and dismutation by SOD, hydrogen peroxide (H2O2) is also rapidly generated. While H2O2
easily cross the biological membranes, the negatively charged O2
-  does not permeate the lipid bilayer of membranes.
However, O2
-  is able to pass through the pore of anion channels (ACs), such as voltage-dependent mitochondrial AC. H2O2
can be transformed to the more dangerous OH. Superoxide anion can react with NO to generate ONOO- and other RNS.
Either redox stress or redox signaling can occur on both sides of membrane. However, it must be borne in mind that the
switch from redox signaling to redox stress (within and outside mitochondria) does not depend only by the type of ROS/RNS
but also on the amount of ROS/RNS and the vicinity of targets and antioxidants. Several isoforms of SOD degrade O2
-  to
H2O2, including manganese (MnSOD) in the matrix and copper/zinc SOD (CuZnSOD) in the intermembrane space and
cytosol. In the matrix, H2O2 is further detoxified to water primarily by glutathione peroxidase (GPX) and by catalase (CAT).
The thickness of dotted lines represents the ability to diffuse through the membrane. For other acronyms, see the list of
Abbreviations Used.
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members (STAT-1, STAT-2, STAT-3, STAT-4, STAT-5A,
STAT-5B, and STAT-6), all expressed in the heart. STATs are
tyrosine phosphorylated by activated Janus kinases ( JAKs),
which allow them to form homodimers or heterodimers that
translocate to the nucleus, resulting in gene transcription. In
fact, the activation of the JAK/STAT pathway plays a pivotal
role in the expression of stress-responsive genes. While the
activation of STAT-1 is associated with apoptosis, the acti-
vation of STAT-3 affords cardioprotection [for reviews see (28,
107, 156, 258)]. The localization of STAT proteins in the heart
is not restricted to the cytosol and the nucleus; recently, they
have also been identified in cardiomyocyte mitochondria (29,
373). The majority of studies investigating the role of STAT
proteins in cardiac function have focused on STAT-3, which
plays a role in apoptosis, heart failure, hypertrophy, post-
partum cardiomyopathy, and I/R injury (28, 34, 155, 352).
Recently, a role for STAT-5 activation in cardioprotection has
been evidenced in humans (148).
The cardioprotective role of STAT-3, which activates ex-
pression of antiapoptotic, antioxidative genes, has been pre-
viously reviewed (e.g., 28, 34, and 137). In the present section
of the review, only STAT-3 targeting mitochondria will be
considered. Effects of STAT-3 on the nucleus in relation to
cardioprotection will be considered in the section VIII, dedi-
cated to SWOP.
Besides RISK (Akt/ERK/GSK-3b) and PKG/PKC path-
ways in both PreC and PostC, another cardioprotective
pathway involves tumor necrosis factor (TNF)-a, sphingosine,
and the JAK/STAT-3 system, which Lecour has called the
SAFE pathway (212). SAFE may interact with the other pro-
tective pathways, and a cross-talk between PI3K/Akt and
STAT-3 has been proposed (137). Therefore, STAT-3 acts as
both signaling molecules and transcriptional regulators,
transducing stress signals from the plasma membrane to both
the nucleus and to the mitochondria, predominantly in the
mitochondrial matrix (29). The important role of STAT-3 in
cardioprotection may be in part mediated by its effects on
mitochondrial respiration and mPTP opening. In fact, inhi-
bition of mitochondrial STAT-3 reduces ADP-stimulated
respiration of myocardial mitochondria and calcium-induced
mPTP opening (29). Effects of STAT-3 on mitochondrial res-
piration have been extensively reviewed in a recent article of
Szczepanek et al. (344). It seems that STAT-3 is necessary for
the optimal activity of complexes I and II of the electron
transport chain (ETC). STAT-3-deficient embryos die because
of defects of the visceral endoderm. To overcome the problem
of embryonic lethality, cardiomyocyte-specific STAT-3-KO
mice were generated (181). STAT-3 deletion in cardiomyo-
cytes attenuates integrated respiration due to a decrease in the
enzymatic activities of complexes I and II (373). The over-
expression of mitochondrial-targeted STAT-3 in mice also
results in a partial inhibition of electron transport at com-
plexes I and II that does not affect baseline mitochondrial
membrane potential nor enhance the production of ROS. It
seems, however, that this inhibition may attenuate the pro-
duction of ROS from complex I during I/R. In fact, the tar-
geting of transcriptionally inactive STAT-3 to mitochondria
may attenuate injury to mitochondria during cell stress, re-
sulting in decreased production of ROS and less release of Cyt
c from mitochondria (343). Since cyclosporine A (CsA) re-
duces the infarct size to a similar extent in wild-type and
STAT-3-KOmice (29), it is likely that Cyp-D, the target of CsA,
is downstream of STAT-3. Boengler et al. also suggest that
some protein kinases could be a possible target of STAT-3
within mitochondria (29).
Recently, Bolli and coworkers (36) reported the develop-
ment of tamoxifen-inducible, cardiomyocyte-specific STAT-3-
deficient mice. This inducible model represents an attractive
model, since it overcomes both the problems of embryonic
lethality and the consequences of chronic alterations in gene
expression, which may induce adaptive phenotype modifi-
cations. These mice are free of alterations in apoptosis, fibro-
sis, capillary density, cardiac function, and cardiac
hypertrophy or dilatation 35 days after the end of the induc-
tion treatment with tamoxifen. Therefore, these animals may
be of great value to study the role of STAT-3 in the cardio-
protection by ischemic PreC and PostC without the con-
founding effects associated with a chronic STAT-3 deletion.
Actually, Bolli and coworkers (36) in this seminal work used
this model to study the SWOP (see SWOP; section VIII).
The potential interaction of the RISK, PKG/PKC, and SAFE
pathways and their mechanistic relation remain to be defined
(137). However, all pathways appear to converge ultimately
on the mitochondrion. Whether ischemic PreC and PostC in-
duce a translocation/phosphorylation of STAT-3 into mito-
chondria is unclear at present. Nevertheless, the targeting of
STAT-3 to mitochondria unveils a novel protective approach
that is independent of STAT-3 transcriptional activity. The
potential beneficial effects of mitochondrial STAT-3 in pro-
tecting the myocardium against I/R-mediated damage need
further investigation.
4. Pim-1 kinase in the I/R scenario and cardioprotec-
tion. The proto-oncogene serine/threonine-protein kinase
Pim-1 is not yet included in the classical (RISK and SAFE)
cardioprotective pathways. This is a kinase that belongs to the
family of calmodulin-dependent protein kinases. With Pim-1,
a new protein kinase has been identified that increases in the
mitochondria after I/R. In fact, the mitochondrial content of
Pim-1 is enhanced after I/R in vitro, and mitochondria iso-
lated from mouse hearts overexpressing Pim-1 are more re-
sistant to Ca2 + -induced swelling than mitochondria from
wild-type mice (234). Pim-1 operates downstream of Akt, and
a feedback mechanism exists involving the two proteins. In
fact, Akt is an upstream activator of Pim-1 kinase, and Akt
expression and phospho-Akt(Ser473) levels increase in re-
sponse to Pim-1 overexpression. Similarly, increased levels of
phospho-Akt(Ser473) are found in myocardial sections from
mice with global genetic deletion of Pim1. Actually, increased
levels of phospho-Akt(Ser473), phospho-Akt(Thr308), and
total Akt are seen in whole-heart lysates from Pim-1-KO
samples (234). Pim-1 inactivation may increase apoptotic ac-
tivity via increased generation of mitochondrial ROS and
mPTP opening, as found in other cellular contexts (217, 234).
Pim-1 may also act, in part, as a normal upstream regulator of
the expression of Bcl-2 (217). Up to now, information on mi-
tochondrial Pim-1 in I/R is scant, and it is unclear whether or
not PreC and/or PostC impacts on themitochondrial contents
of Pim-1. Overexpression of Pim-1 was found to protect the
myocardium after infarction injury and cardiomyocytes from
apoptotic challenge by increasing cell survival signaling (274).
While genetic ablation of Pim-1 increased the myocardial in-
farct size after I/R in vivo (234), its pharmacological inhibition
with Pim-1 kinase inhibitor II [2-hydroxy-3-cyano-4-phenyl-
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6-(3-bromo-6-hydroxyphenyl)pyridine] blocked the cardio-
protection by PreC (336). We reported that PostC increases
the levels of antiapoptotic markers, including Pim-1 and Bcl-2
(274).
5. Bcl-2 family: interaction with mitochondria. The Bcl-2
family consists of three classes of Bcl-2 proteins that can reg-
ulate apoptosis. These are (i) inhibitors (e.g., Bcl-2 and Bclxl);
(ii) promoters (e.g., Bax and Bak); and (iii) regulators of the
antiapoptotic Bcl-2 proteins such as proteins sharing the BH3
motif (e.g., Bad, Bid, and Bim). These proteins may act as
activators or inhibitors of cell death (386). The promoters of
apoptosis, Bax and Bak, induce caspase activation via induc-
tion of the so-calledmitochondrial apoptosis-induced channel
(MAC) that is distinct from themPTP, though alsomPTPmay
be regulated by Bcl-2 family proteins (194). It is thought that
Bax interacts with an activator such as Bid (325), which in-
duces a conformational change in Bax, resulting in insertion
into the OMM, to formMAC. Release of factors, such as Cyt c
and apoptosis-inducing factor (AIF), from the mitochondrial
intermembrane space, results in fission of mitochondria into
smaller fragments (386). AIF, adenylate kinase, Cyt c, deaf-
ness dystonia protein (DDP), Endo G, and DIABLO (also
known as Smac) have all been reported to be released from
the mitochondrial intermembrane space into the cytosol
of cells undergoing apoptosis (50, 386). In particular, Cyt c
and AIF when released from mitochondria bind to apoptotic
peptidase-activating factor 1 (APAF1) (50, 386). This will
lead to the assembly of the so-called apoptosome (a hepta-
meric protein ring), which will bind and activate caspase 9.
Therefore, once activated, caspase 9 triggers a caspase cas-
cade, which primes the cell for apoptosis (371). A caspase-
independent apoptosis is obtained by the mitochondrial
release of other factors, such as AIF and Endo G (50). Smac/
DIABLO released frommitochondria may inhibit the intrinsic
inhibitor of apoptosis proteins (IAPs), thereby neutralizing
IAPs’ caspase inhibitory properties. This may sustain a vi-
cious cycle that could continue to lead to more apoptosis. This
vicious cycle could be interrupted by the antiapoptotic Bcl
family proteins by acting on the OMM, thus reducing Cyt c
release and subsequently reducing Smac/DIABLO release
and decreasing apoptosis (50).
The involvement of Bcl-2 family in the I/R scenario and
protection has been extensively studied (119, 194, 217, 274).
These studies suggest an important role in reperfusion-in-
duced apoptosis. Both PreC and PostC limit reperfusion in-
jury affecting all form of cell death, including apoptosis (6,
274, 355, 392). Of course, reperfusion must be applied as soon
as possible. In fact, both beneficial and deleterious effects of
reperfusion as well as protective effects of PostC depend
critically on the duration of index ischemia (125, 134, 174, 226,
277, 329). The loss of mitochondrial membrane potential and
matrix swelling caused by mPTP opening induce the release
of the proapoptotic proteins from the intermembrane space
into the cytosol, which ultimately leads to the activation of
caspase-mediated apoptosis. Therefore, the Bcl-2 family is of
paramount importance in regulating cardioprotection. A di-
rect link between the induction of PreC to protect against I/R
injury and GSK-3b phosphorylation-dependent modulation
of mitochondrial Bcl-2 protein levels has been demonstrated
(75). Also, PKG activation and enhanced phosphorylation of
GSK-3b, with a subsequent increase in the Bcl-2/BAX ratio,
were implicated in PreC induced by inhibition of phospho-
diesterase-5 (73). We were among the first to report a Bcl-2
increase and cleaved caspase-3 decrease in PostC (274). It has
been also reported that PostC may reduce myocardial apo-
ptosis during reperfusion via a JAK-STAT-3-Bcl-2 pathway
(355). Further studies focusing on other proteins of the Bcl-2
family may be helpful to define the long-term benefit of PostC
against apoptosis (192, 338).
6. AMP-activated protein kinase, a metabolic regulator
in health and disease. AMPK phosphorylates multiple
targets, including several biosynthetic enzymes and cardio-
protective elements, such as acetyl-CoA carboxylase, hydro-
xymethylglutaryl-CoA reductase, glycogen synthase, and
endothelial nitric oxide synthase (eNOS) (53). In Figures 6 and
7 are reported some of the multiple targets of activated
AMPK.
Usually AMPK is activated when the AMP concentration
increases as a result of insufficient ATP production or un-
matched energy demand. Therefore, it plays a role of para-
mount importance in the regulation ofmitochondrial function
during and after ischemia when the ATP/ADP/AMP un-
dergoes abrupt changes. Although, its main role is to monitor
the mitochondrial function and cellular energy status re-
sponding to changes in the AMP/ATP ratio, AMPK can also
be activated independently of adenine nucleotides, by chan-
ges in calcium concentrations as well as by increased pro-
duction of ROS (16).
AMPK is a heterotrimeric complex that contains a catalytic
(alpha) and two regulatory (beta and gamma) subunits. Each
FIG. 6. AMP-activated protein kinase (AMPK) activation.
AMPK is formed by a-, b-, and c-subunits. An increased
AMP-to-ATP ratio leads to a conformational change in the c-
subunit, leading to increased phosphorylation and decreased
dephosphorylation of AMPK. This activation facilitates the
activity of PKC of which AMPK is a substrate. Additional
regulation is affected by Ca2 +–calmodulin-dependent kinase
kinase b (CaMKKb), which phosphorylates and activates
AMPK in response to increased Ca2 + . Activated/phosphor-
ylated AMPK enhances free fatty acid (FFA) oxidation, im-
proves NO availability, and may limit ROS production via
several different pathways (see also Fig. 7). Once activated,
AMPK can download the NFjB-signaling system. For other
acronyms, see the list of Abbreviations Used.
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subunit has multiple isoforms (a1 and 2, b1 and 2, and c1, 2,
and 3). Therefore, 12 possible combinations of AMPK holo-
enzyme are described in murine and human hearts. The
catalytic alpha subunit includes both the protein kinase
domain and a threonine residue (Thr172) whose phosphor-
ylation by kinases is responsible for AMPK activation. Fig-
ure 6 shows the main factors controlling the shift from
inactive to active AMPK. It seems that in human hearts, both
AMPK a1 and 2 catalytic subunits contribute to the total
AMPK activity. On the contrary, in mouse hearts, a2 sub-
unit accounts for about 80% of total AMPK activity (16). The
b subunit acts as a scaffold for the other two subunits. It also
contains a glycogen-binding domain whose physiological
role might be to control glycogen metabolism. AMPK is
present in the nucleus and the cytoplasm; however, the
mechanisms that regulate the intracellular localization of
AMPK are unknown.
It seems that environmental stresses regulate the intracel-
lular localization of AMPK, and upon recovery from heat
shock or oxidant exposure, AMPK accumulates in the nuclei.
Treatment with an AMPK activator increases the expression
of peroxisome proliferator-activated receptor c coactivator
(PGC)-1a and manganese superoxide dismutase (MnSOD)
mRNAs, which may inhibit ROS production in mitochondria
(204). Since AMPK serves as an energy sensor, it is at the
center of control for a large number of metabolic reactions,
thereby playing a crucial role in metabolic syndrome (MS),
Type-2 diabetes, and other human diseases.
The activation of AMPK induces acceleration of mito-
chondrial biogenesis in physiological conditions. Conditions
leading to changes in AMP concentrations and AMPK acti-
vation are directly related to changes in ATP concentrations.
Accordingly, ischemia, similarly to mitochondrial respiration
inhibitors, activates AMPK within a few minutes (131). In-
creased ATP demand also leads to AMPK activation, espe-
cially when combined with decreased ATP supply, as is the
case in contracting muscle during hypoxia. Also, intense ex-
ercise, norepinephrine, phenylephrine, isoproterenol, or va-
sopressin activates heart AMPK (183). In Figure 7 are reported
some of the pathways able to activate AMPK and some of the
AMPK metabolic targets.
When activated, AMPK aims to restore the cellular energy
charge by switching off anabolic ATP-consuming pathways.
Although the mechanism remains to be elucidated, AMPK
could inhibit (i) cJUN kinase activation; (ii) endoplasmic re-
ticulum stress; and (iii) oxidative stress in several cellular
models, including cardiomyocytes (86). Activated AMPK
may also inhibit glucose-induced oxidative stress and
NADPH oxidase activation in endothelial cells (51). On the
other hand, AMPK may switch on catabolic ATP-producing
pathways. For these reasons, it may play a role in cell pro-
tection. Recently, it has been demonstrated that the AMPK-
dependent mitochondrial protection of resveratrol against
oxidative stress may be associated with the downstream in-
hibitory phosphorylation of GSK-3b (322). Although the
mechanism of resveratrol’s cytoprotection involves AMPK
FIG. 7. AMPK signaling in controlling the metabolic state. AMPK regulates protein synthesis, glycolysis, fatty acid
oxidation, and lipolysis. AMPK activity is influenced by exercise and hypoxia, likely with the intervention of hormones and
metabolites. Here are reported some of the metabolic targets and signaling pathways of AMPK. Activated AMPK has a
plethora of targets; for instance, AMPK is a central regulator for cell growth and metabolism via multiple targets, including
mTOR (the target of rapamycin), which resides in the two functionally distinct complexes TORC1 and TORC2 (defined by
their adaptors Raptor and Rictor, respectively). The two TORCs are affected with unknown modalities. AMPK is also
implicated in suppression of initiation and progression of cancers in various tissues via the regulation of the inhibitor of
growth (ING) family, an evolutionarily conserved set of proteins. ROS may be activators of AMPK, and activated AMPK may
limit ROS production (see Fig. 6 and text). In bold are reported some targets directly involved in cardioprotection (see text).
Therefore, AMPK may play a pivotal role in protection and deserves more attention by researchers. PFK2, Phospho-
fructokinase 2; P70 SGK, glucocorticoid-inducible kinase. For other acronyms, see the list of Abbreviations Used.
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activation, resveratrol does not directly activate AMPK
in vitro (15). It is likely that redox conditions play a role in this
mechanism (see section II.C).
B. Important components of mitochondria
in the network involved in I/R and cardioprotection
Kinases may be imported into mitochondria and/or may
affect directly and indirectly the function of mitochondrial
components (e.g., mPTPs and mKATP channels). Here, we
consider more details of these components. However, a
challenge is that many mitochondrial channels and trans-
porters have yet to be identified at the molecular level.
1. Mitochondrial permeability transition pore. This pore is
a high-conductance megachannel, which, as said, plays a role
of paramount importance in the I/R scenario. Themodulation
of mPTP is also important physiologically in regulating the
calcium homeostasis. The pore modulation and opening will
be considered with more detail below (sections III.A, III.B,
and III.C); here, we consider the putative components of
mPTPs and their interaction. The pore was first described in
1976 by Hunter et al. (167) and is located between the inner
and OMMs. When an mPTP is formed, it opens and allows
communication between the cytoplasm and the mitochon-
drial matrix. The molecular identity of the proteins that form
this pore is still unknown. It has been suggested that the
mPTP is formed by the VDAC in the OMM, the ANT in the
IMM, and Cyp-D in the matrix of mitochondria. When the
mPTP is in the closed state, the matrix protein Cyp-D is de-
tached from IMM, whereas HK II is attached to OMM com-
ponents of the pore (Fig. 8A). Opening of mPTP (Fig. 8B)
appears to be facilitated by the binding of Cyp-D to the IMM
in a process regulated by both Ca2 + and inorganic phosphate
(Pi) (78). However, experiments with transgenic mice in each
of the components of the putative mPTP achieved contro-
versial results. In fact, neither the deletion of the gene nor
knockdown of VDAC or ANT prevents mPTP opening in
response to Ca2 + overload of mitochondria (7, 8, 197, 243). In
fact, experiments with VDAC and ANT KO mice demon-
strated substantial permeability transition during Ca2 +
stimulation, indicating that VDAC and ANT are not essential
for the permeability transition (7, 8, 197). However, these
experiments are not conclusive, and the dispute is not re-
solved. While in fibroblasts and liver mitochondria of KO
mice Cyp-D Ca2 + -induced mPTP opening is overdue (7, 12),
the sensitivity of mPTP opening in response to adenine nu-
cleotides or oxidative stress is similar in Cyp-D-deficient
and wild-type mitochondria, indicating that Cyp-D is im-
portant for mPTP opening, but that the permeability transi-
tion can occur even in the absence of Cyp-D (12). The
possibility that Cyp-D has a role in the regulation of apoptotic
proteins in a manner that is independent of the mPTP has
been suggested (98).
FIG. 8. mPTP composition and regulation. In Figure 1 are reported the factors controlling the mPTP-opening probability.
Here are evidenced the putative elements that form the pore. The mPTP is believed to be composed of the ANT in the IMM,
the VDAC in the OMM, and Cyp-D in the matrix. (A) In physiological conditions, Cyp-D is detached from IMM, and HK is
attached to the OMM. Notably during ischemia, mPTP opening hardly occurs because mPTP is strongly inhibited by acidosis.
(B) mPTP typically opens in reperfusion when Ca2 + overload, generation of ROS, and pH normalization occur. Ca2 +
overload may stimulate the interaction of Cyp-D with other mPTP components, which triggers permeability transition. A
part Ca2 + overload, also inorganic phosphate (Pi), contributes to mPTP opening through the binding of Cyp-D to the inner
membrane. Also, HK detachment from mitochondria triggers apoptosis through mPTP opening. In fact, pore opening leads
to cell death through the release of proapoptotic factors and via RIRR (ROS-induced ROS release). Other important factors
that regulate pore formation are Bax/Bad/Bcl-2 and GSK-3b. Cytochrome c and other mediators are simultaneously released
that may play a role in committing the cell to death. These mediators include Smac/Diablo and AIF. For further explanations,
see the text and Figure 9. For other acronyms, see the list of Abbreviations Used.
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2. Putative mitochondrial ATP-sensitive potassium chan-
nels. Abundant in myocardial sarcolemma, where they
were originally discovered (305), ATP-sensitive potassium
(KATP) channels have also been reported to reside within in-
tracellular membranes, including endoplasmic/sarcoplasmic
reticulum, nuclei, secretory granules, and mitochondria (78).
KATP channels are biosensors that enable high-fidelity read-
out of metabolic distress signals (115, 347, 369). It is likely
that these channels behave like checkpoints that perform
a rheostat-like operation adjusting membrane potential-
dependent functions to match energetic demands of the
working heart (124, 128, 236). KATP channel complexes are
formed by KCNJ11-encoded Kir6.2 pore subunits coas-
sembled with the regulatory ATP-binding cassette sulfonyl-
urea receptor; channel deficit impairs tolerance to endurance
challenge, hemodynamic load, or sympathetic discharge (70,
126, 200, 207, 285, 286). Both sarcolemmal and putative
mKATP channels comprise the protective benefit of ischemic
PreC and PostC, (7, 27, 82, 146, 197), whereas disruption of the
KATP channel blunts this protective response (197, 243). Be-
cause of the central role of mitochondria in cardioprotection,
much attention has been devoted to mKATP channels.
Mitochondrial ATP-sensitive K+ channels are located in the
IMM, are considered targets of protective signaling pathways,
and play a pivotal role in ROS production, mainly O2
-  de-
rived from complex I of the ETC (27, 117, 274, 310, 383).
Opening of themKATP channels and subsequent generation of
ROS are considered to be a pivotal step in the mechanisms of
PreC and PostC (27, 270, 382). We evidenced that ROS sig-
naling is downstream of mKATP channel opening in isolated
rat hearts subjected to I/R with an intermittent infusion of
mKATP channel opener, diazoxide, or diazoxide plus the ROS
scavenger mercaptopropionylglycine (MPG) at the onset of
reperfusion. In fact, MPG attenuated diazoxide-induced
protection (271).
In the context of cardioprotection, it has been reported that
Akt-dependent phosphorylations and subsequent PKG acti-
vation lead to mKATP channel activation. Actually, Akt and
PKG are a part of the so-called signalosomes (113), which are
vesicular, multimolecular signaling complexes, involving the
assembly and regulation of multiproteins, which compart-
mentalize and convey the intracellular signal (296). Whether
or not these proteins form a signalosome, they also include
eNOS, guanylyl cyclase, and cyclic guanosine monopho-
sphate (cGMP), which activates PKG. Indeed, it has been
proposed that activated PKG phosphorylates an unknown
protein of the OMM (113). This causes the signal to be trans-
mitted to PKCe already bound to the IMM, which in turn
causes the mKATP channel opening. (66–68, 113).
For the mKATP channel opening, the protective signal is
transmitted from the OMM to the IMM. This may be accom-
plished by a series of intermembrane-signaling steps that in-
cludes PKCe activation, so that stimulation of mitochondrial
K + influx via the mKATP channels is cardioprotective, and
activation of themKATP channel is mediated bymitochondrial
PKCe (Fig. 9). The resulting ROS then activate a second PKC
pool, which through another signal transduction pathway
causes inhibition of mPTPs (one of the end effectors) and re-
duction in cell death. In summary, the inhibition of mPTP
opening occurs through intermediary steps involving PKCe,
mKATP channels, K
+ entry into mitochondria, matrix alkali-
zation, and generation of ROS with a protective signaling role
(Figs. 3 and 9) (66–68, 72, 113, 253, 270, 382). Pharmacological
opening of mKATP channels by diazoxide contributes to the
formation of small amounts of ROS inducing cardioprotection
(74, 109, 129, 142, 143). Also NO donors can activate mKATP
channels in rabbit ventricularmyocytes and can potentiate the
protective effect of themKATP channel opener diazoxide (310).
Besides cGMP/PKG-dependent phosphorylation, mKATP
channels can be opened by direct reaction of NO and
FIG. 9. Signaling pathways
in cardioprotection: reperfu-
sion injury salvage kinases
(RISKs) and survivor-
activating factor enhance-
ment (SAFE). Activation of
cell surface receptors (e.g.,
Ade, BK, erythropoietin
[EPO], tumor necrosis factor
[TNF], and interleukin-6 [IL6])
in response to a PreC or PostC
stimulus may recruit both the
RISK and the SAFE pathways.
Ligands of membrane recep-
tors initiate cardioprotection
by activating a cascade of ki-
nases, leading to mPTP inhi-
bition, and thus protecting the
cell against apoptotic and ne-
crotic death. These two path-
ways are activated at the time
of reperfusion and will cross-
talk. See also the text. For
other acronyms, see the list of
Abbreviations Used.
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derivatives and by the action ofH2S, leading to S-nitrosylation
(SNO) and S-sulfhydration of proteins, respectively [for re-
view see (260)].
It has been suggested that mKATP channels are activated by
ROS: O2
-  and H2O2, but not other peroxides. Yet, certain
RNS can activate mKATP via a mechanism involving mito-
chondrial complex II. Moreover, mKATP channels are in-
hibited by NADPH. Thus, to sum up, mKATP channels are
activated by S-nitrosothiols, nitroxyl, and nitrolinoleate (102,
110, 292, 389). The latter two species also inhibit mitochon-
drial complex II. Nitroxyl protects cardiomyocytes against IR
injury in an mKATP-dependent manner. Overall, these results
suggest that the mKATP channels are activated by ROS and
RNS and inhibited by NADPH. The redox modulation of
mKATP channels may be an underlying mechanism for its
regulation in the context of PreC and PostC (295).
However, controversy exists on the nature, existence, and
opening of mKATP channels, which may also be a deleterious
process (72, 74). In fact, for instance, mKATP channels are
suggested to be involved in angiotensin II-induced redox
stress via the depolarization of mitochondrial membrane po-
tential and consequent respiratory dysfunction (182, 216).
Moreover, the mKATP channel opener diazoxide caused a ni-
trate tolerance-like phenomenon, whereas the KATP channel
inhibitor glibenclamide improved tolerance in nitroglycerin-
treated animals (71). Finally, diazoxide and/or 5-HD, channel
agonist and antagonist, respectively, may also have direct
effects on mitochondrial ETC and mitochondrial bioenerget-
ics (129, 130). Thus, these drugs lack specificity for the chan-
nel, and cautions are needed in this respect.
Hence, it seems that on the one hand, mKATP channel
opening induced by PKC activation stimulates ROS produc-
tion, whereas on the other hand are ROS generated in the
cytosol that stimulate mKATP channel opening. A simple
model in which the first mechanism may be protective while
the second would be detrimental could be suggested. How-
ever, PKC activation leading to the opening of mKATP chan-
nels has been challenged by the Halestrap group: they
demonstrated that PreC inhibits opening of the mPTPs in situ
by an indirect mechanism probably involving decreased ROS
production and Ca2 + overload at reperfusion (74, 128).
Therefore, based on these observations, one can speculate that
mKATP channel activation by PKC is not required to induce
protection. Nevertheless, several studies have shown that
redox-dependent opening of the channel is a protective
mechanism [for reviews see (66, 67, 295)].
Clearly, further work in this area, including the molecular
identification of the mKATP channel itself and the redox-sen-
sitive residues within it, will facilitate a better understanding
of the role that regulation of the channel plays in events such
as cardioprotection.
3. Mitochondrial Cx43. A component that has been as-
sociated with the mKATP channel structure and function is
mitochondrial Cx43 (mCx43). Indeed, within cardiomyocytes,
Cx43 is mainly localized in the cellular membrane at gap
junctions. Cx43 is formed by four transmembrane domains,
two extracellular and one intracellular loop, as well as cyto-
solic amino- and carboxytermini. Cx43 is the target of differ-
ent kinases, among them protein kinase A (PKA), PKC, and
MAPKs, which phosphorylate Cx43 sites mainly located
within the carboxyterminus [for a review, see (331)].
However, Cx43 is also present in other organelle mem-
branes, including the IMM of a subset of cardiomyocyte mi-
tochondria, that is, subsarcolemmal mitochondria (26, 32,
222), where Cx43 regulates mitochondrial K + fluxes (232,
304). Cx43 presence has not been observed at the inner
membrane of cardiomyocyte interfibrillar mitochondria (32).
Whether the half-life of mCx43 is similar to that of gap-junc-
tional Cx43 (about 90min) is unknown at present. The path-
way by which Cx43 is imported into subsarcolemmal
mitochondria involves Hsp90 and Tom20 (32, 274). Since the
inhibitor of Hsp90, geldanamycin, reduces the mCx43 content
in hearts perfused under normoxic conditions, it is possible
that Cx43 is continuously imported into mitochondria.
Interestingly, mCx43 coimmunoprecipitates with GSK-3b
(32). mCx43 has also been implicated in ROS signaling,
though its role is not completely defined (27, 28, 32). It has
been suggested that Cx43 may form the pore of mKATP
channels (304). In fact, mitochondrial PKCe phosphorylates
Cx43, and the PKCe-mediated activation of the mKATP chan-
nel requires Cx43 (66). As said above, opening of the mKATP
channel contributes to cardioprotection via the formation of
small amounts of ROS, which function as trigger molecules of
PreC and PostC. However, since the open probability of the
channel is not dependent on Cx43 under basal conditions, it is
unlikely that Cx43 represents the pore-forming unit of the
mKATP channel (32).
mCx43 has been described to be essential for PreC protec-
tion (142, 143, 301, 318), but a study (146) in mice heterozy-
gous for Cx43 (Cx43 +/ - ) indicates that it does not play a
significant role in PostC protection. Actually, Cx43 is a target
of several protein kinases, and mCx43 is highly phosphory-
lated under physiological conditions (357); it seems that in the
IMM of subsarcolemmal mitochondria, the phosphorylated
portion of Cx43 increases with ischemia (32) and decreases
with PostC (274). Since a decrease of the mCx43 content is
sufficient to abolish the cardioprotection by diazoxide PreC,
that is, reduces ROS formation (142, 143), one can speculate
that mCx43 reduction in PostCmay be one of the mechanisms
to reduce excessive ROS production in the reperfusion phase.
Recently, it has been suggested that genetic ablation or
pharmacological inhibition of mCx43 confers resistance to
mKATP channel opening in response to diazoxide in patch-
clampedmitoplasts (mitochondria devoid of the OMM) (304).
However, the open probability of the mKATP channel was not
affected under baseline conditions; thus, it is likely that
mCx43 regulates this channel activity rather than constituting
the pore-forming unit of the mKATP channel (304). Cardiac
cells from heterozygous Cx43-deficient mice do not form
sufficient amounts of ROS when stimulated by diazoxide and
accordingly, have no cell death reduction after I/R in vivo.
Ischemic PreC increases the amount of mCx43 after short in-
termittent cycles of PreC ischemia in rat hearts in vitro and
after infarcting ischemia in pig hearts in vivo. In this latter
species, I/R is associated with increased dephosphorylation
of mCx43, and ischemic PreC preserves Cx43 phosphoryla-
tion at Ser368 (74, 129, 143). However, enhanced mCx43
content after PreC seems not a prerequisite for cardioprotec-
tion. It is rather the decrease of Cx43 below a certain threshold
level that should be avoided to allow the ROS-triggered
protection of the heart by PreC.
The role of mCx43 in ischemic PostC has not been clearly
characterized up to now. We demonstrated that decreased
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amounts of total Cx43 in mitochondria isolated from post-
conditioned (five cycles of 10-s ischemia and reperfusion each)
rat hearts underwent 30-min ischemia and 120-min reperfu-
sion in an ex vivo model (274). The reduced amounts of total
Cx43 were paralleled by reduced amounts of Cx43 phos-
phorylated at the epitope Ser368. Heusch et al. (146) have
studied the Cx43 content in mitochondria isolated from
mouse hearts subjected to 30-min ischemia and 10-min re-
perfusion without and with PostC (three cycles of 10-s is-
chemia and reperfusion each) in vivo. In this model, PostC
increased both the levels of total Cx43 and of Cx43 phos-
phorylated at Ser368. However, ischemic PostC reduced the
infarct size in heterozygous Cx43-deficient hearts to a similar
extent as in wild-type hearts.
Therefore, physiological amounts of mCx43 are impor-
tant for effective cardioprotection by ischemic and phar-
macological PreC. mCx43 plays an important role in PreC
likely via modulation of the opening of mKATP channels
and subsequent ROS signaling. The role in PostC is less
clear. We suggest that an initial involvement and a subse-
quent decrease of the amounts of mCx43 may play a role
in PostC, underpinning the initial triggering role of ROS
signaling and the subsequent reduction of redox stress.
Alternatively, changes in the amount of total or phos-
phorylated Cx43 may be an epiphenomenon associated
with ischemic PostC.
4. Mitochondrial uncoupling proteins. Other mitochon-
drial components associated with ROS production are the
uncoupling proteins (UCPs). Under physiological conditions,
mitochondrial oxygen consumption (VO2) is coupled to ATP
synthesis. Reducing equivalents, resulting from energy sub-
strate oxidation, deliver electrons to the mitochondrial ETC.
The energy resulting from electron transfer to oxygen atom is
used to generate an electrochemical gradient by pumping
protons from the mitochondrial matrix into the intermem-
brane space. Under physiological conditions, the protons re-
enter the matrix via F0F1-ATPase, which uses the energy to
regenerate ATP from ADP (Fig. 10). In addition, a small
proportion of H + can bypass F0F1-ATPase, so that VO2 is not
strictly coupled to ATP synthesis. In the 1970s, H + traslocases
were identified in the IMM of brown adipose tissue and
named UCPs, which are present in the mitochondria of dif-
ferent tissues and have different homologs. There are four
UCP variants believed to induce inward H + leak in energized
mitochondria. Their main role is to direct the mitochondria to
produce heat rather than ATP, that is, there is an H + influx
into the mitochondrial matrix without phosphorylation of
FIG. 10. F0F1-ATPase and ETC function in ischemia and reperfusion with and without protection. F0F1-ATPase uses the
energy of the proton–electrochemical gradient (DH + ) across the IMM to regenerate ATP from ADP. During ischemia, it can
work in a reverse mode and consumes ATP. During reperfusion, F0F1-ATPase and ETC restart to produce ATP and ROS in a
variable quantity, whether the heart is protected or not. In nonprotected reperfusion when mPTP is opened, F0F1-ATPase can
work in a reverse mode. The thickness of arrows indicates the prevalent fuel utilized (in bold) and the molecules produced (in
bold-italic) by mitochondria. TCA, tricarboxylic acid cycle. For other acronyms, see the list of Abbreviations Used.
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ADP. As such, UCPs are important metabolic regulators in
permitting fat oxidation and in attenuating free-radical pro-
duction. Since ROS production increases with increasing
membrane potential, UCP-mediated uncoupling has been
proposed to play a role in regulating mitochondrial ROS
production and may represent a mechanism by which mito-
chondria protect themselves from oxidative damage (40,
317). Among ROS-derived lipid peroxidation products, 4-
hydroxynonenal (HNE) is considered an important mediator
of free-radical damage (101). It has been suggested that cy-
totoxic HNE is also able to act as a signaling agent, inducing
mitochondrial uncoupling via the UCP1, UCP2, UCP3, and
ANT (94). Themechanism of induction of proton leak byHNE
is unclear. It has been suggested that HNE may induce co-
valent modification and conformational changes in the UCPs
that allow the passage of protons back into the mitochondrial
matrix (95). Both UCP2 and 3 are expressed in the heart, but
their role is unclear. Although controversy exists on the car-
dioprotective role of uncoupling, mild uncoupling secondary
to activation of UCPs has been described to confer cardio-
protection under several conditions, including myocardial
reperfusion, likely by decreasing ROS production (157). For
instance, both ONOO - and electrophilic lipids can activate
cardioprotective mitochondrial mild uncoupling (41, 229)
Moreover, conditions occurring during PreC, such as elevated
NO, transient ROS generation, acidic Ph, and the activation
of both mitochondrial phospholipase A2 and lipoxygenases
(63, 237, 376), could favor nitroalkene generation from the
polyunsaturated fatty acids in mitochondrial membranes.
Nitroalkenes formed in mitochondria during ischemic PreC
nitroalkylated ANT and UCP2, leading to mild uncoupling
and cardioprotection against I/R injury (240). Yet mitochon-
drial uncoupling contributes to reduced ROS formation (306).
Intriguingly, it has been suggested that transient complex I
inhibition during reperfusion is cardioprotective via attenu-
ated ROS production (324). Moreover, conditions leading to
elevated NO, transient ROS generation, acidic pH, and thus
to mitochondrial uncoupling may occur also in PostC (see
below). Nevertheless, experimental evidence supporting the
involvement of uncoupling in PostC protection has yet to be
provided.
C. ROS/RNS: from mitochondria to activation
of kinases of the network
ROS and RNS such as O2
- , H2O2, and ONOO
- are small
and highly reactive molecules having both physiological
(ROS/RNS signaling) and pathological effects (ROS/RNS
stress) (Fig. 5). In several systems, various pathways, partic-
ularly those involving MAPKs (e.g., JNK, ERK, and p38
MAPK) and PKCs, are modulated by ROS and RNS. It is now
clear that normal levels of cellular ROS and RNS play im-
portant roles in cell-signaling pathways and are vital for
physiological functions. For instance, H2O2 of mitochondrial
origin are of paramount importance in metabolic coronary
vasodilatation (307).
ROS are generated in different cellular compartments and
by several enzymes, including NADPH oxidases at the plas-
ma membrane (211) and cytosolic xanthine oxidases (111).
Although ROS are produced by several extracellular and
intracellular processes, in cardiomyocytes, mitochondria
represent the most relevant site for ROS formation (91, 238,
363–365). It has been suggested that ROS-mediated signals
(mainly by H2O2) arising within mitochondria can also gen-
erate a retrograde response that is conveyed to the nucleus,
causing the upregulation of nuclear genes encoding mito-
chondrial proteins and leading to the induction of mito-
chondrial biogenesis (48). Also, NO is known to induce the
production of O2
-  and H2O2 by mitochondria, and may
trigger redox signaling (46, 48, 240, 241, 294, 300) (see also
below).
Within mitochondria, the largest amount of oxygen is re-
duced to water at respiratory complex IV. Indeed, even under
physiological conditions, a minor fraction of oxygen (< 0.1%)
is transformed into O2
-  at the level of complexes I and III;
SOD then rapidly converts O2
-  to H2O2 that is freely dif-
fusible throughmembranes (110). The production ofH2O2 can
increase during myocardial challenging, such as during in-
creased cardiac work load (307). The further reduction of
H2O2 to OH
 in the presence of transition metals, such as Fe2 +
or Cu2 + , represents a dangerous step, because an increase in
toxicity can occur. In fact, no enzyme is available for the re-
moval of OH that can only be scavenged by antioxidants
with the formation of less-dangerous radical species.
The mitochondrial formation of ROS might be modulated
by NO (46, 294, 300), which reversibly inhibits cytochrome
oxidase (20, 363). This inhibition can be transformed into ir-
reversible alterations of respiratory chain when NO reacting
with O2
-  generates a great amount of ONOO- , an RNS that
can produce irreversible nitration of proteins, including pro-
teins from the oxidative phosphorylation system (18, 220, 362,
391). Under certain conditions, such as scarcity of substrate
and/or cofactors, NOS can become uncoupled, resulting in
the generation of O2
-  and/or OH, instead of NO (18, 379).
Recent evidence suggested neuronal NOS (nNOS) as a protein
completely incorporated to the IMM in a physiological con-
text. In particular, evidence on the presence of an nNOSa
variant in heart mitochondria was provided by Kanai et al.
(188), with the electrochemical determination of the Ca2 + -
induced NO release from a single mouse heart mitochon-
drion, a process that was absent in nNOS -/- KO mice.
Mitochondrial NOS uncoupling has also been postulated
(106), and it could play a role in I/R injury, though this
remains to be demonstrated.
Apart from the ETC, ROS can also be produced in the in-
termembrane space by the apoptosis promoter p66Shc, by
monoamine oxidases (MAOs), and by AIF located in the
OMM (Fig. 5). The p66Shc oxidizes reduced Cyt c, thus in-
ducing the partial reduction of oxygen to peroxide. While
under physiological conditions p66Shc is present in the cy-
tosol, under stress conditions, it can be phosphorylated by
PKCb and translocated into the mitochondrial intermem-
brane space. The monoamine catabolism generates alde-
hydes, ammonia, and H2O2. In fact, MAOs transferring
electrons from amine compounds to oxygen generate H2O2.
AIF comprises NADH oxidase activity and can generate su-
peroxide anion (82, 91, 114, 256).
Besides being a relevant site for ROS formation, mito-
chondrial function and structure are profoundly altered by
oxidative stress (82), especially when mPTPs were undergo-
ing prolonged opening. In fact, mPTPs play a central role in
the so-called ROS-induced ROS release (RIRR) (396–398); ex-
cessive ROS facilitate mPTP opening, which in turn favors
ROS formation by inhibiting the respiratory chain because of
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the mPTP-induced loss of Cyt c and pyridine nucleotides (82,
127). This vicious cycle is likely to be established at the onset of
a rapid reperfusion when a large increase in ROS formation
occurs along with pH recovery and Ca2 + overload, thus in-
ducing injury amplification, as mentioned above and dis-
cussed below (Fig. 1).
ROS are important regulators of PKC by reacting with thiol
groups associated with the zinc-finger region of the molecule
(199). RNS-dependent activation of PKC, possibly via a redox-
sensible SNO process, has been also suggested, a process also
occurring within mitochondria (260, 288, 341). A recent hy-
pothesis considers that H2O2 and aminoimidazole carbox-
amide ribonucleotide (AICAR) treatments phosphorylate and
activate AMPK (99). The H2O2-mediated activation of AMPK
is likelymediated via the ROS-induced decrease in ATP levels.
Endogenously produced ROS within skeletal muscle cells are
important for the maintenance of PGC-1amRNA expression.
The PGC-1 family of regulated coactivators, consisting PGC-
1a and PGC-1b as well as PGC-1a-related coactivator, may
control mitochondrial respiratory function and biogenesis. A
potential link between ROS and the induction of mitochon-
drial biogenesis has been established. In fact, the PGC-1a gene
expression is regulated by ROS, and PGC-1a plays a central
role in regulating the mitochondrial content within cells (312,
335). Also, kinases are involved in mitochondrial biogenesis,
and the most important of these include calcium-/calmodu-
lin-dependent protein kinase IV (378), AMPK (177), and p38
MAP kinase. At least two separate mechanisms are involved
in increasing PGC-1a mRNA expression in response to AI-
CAR. One involves AMPK activation, leading to increases in
PGC-1a promoter activity andmRNA expression. The other is
mediated by a reduction in cellular ROS levels, which leads to
a reduction in the level of PGC-1a mRNA expression. There-
fore, it is likely that the effect of AICAR on PGC-1a gene
expression is a balance between the positive effects of AMPK
activation on promoter activity and its negative effect of ROS,
which may enhance mRNA decay (176).
Also, AMPK-mediated protection could be redox-sensitive:
both H2O2 and increased production of radicals activate
AMPK (99), possibly by oxidation of two cysteine residues in
the alpha subunit of AMPK (395). For instance, it has been
demonstrated that metformin, a drug used to treat type II
diabetes, inhibits complex I of the respiratory chain to gen-
erate mitochondrial O2
- , and then ONOO - , which leads to
AMPK activation via a c-Src- and PI3K-dependent pathway
(400). Subtoxic concentrations of ONOO- generated by met-
formin activate AMPK to precondition the cells, which sub-
sequently reduces the excessive oxidant stress triggered
by hyperglycemia, so that a cross-talk exists between redox
conditions, activity of kinases, and factors promoting mito-
chondrial biogenesis, which, in turn, may regulate ROS and
RNS production in acute and chronic conditions.
Therefore, the key message here is that the signal trans-
duction pathways converge on mitochondria, and are en-
hanced by ROS/RNS. That is, they act as secondary
messengers to control a variety of physiological responses
(redox signaling), such as the regulation of vascular smooth
muscle tone, the regulation of mitochondrial respiration, and
the progression/enhancement of signaling pathways. The
latter involves kinases, such as PKC, MAPK, and AMPK, as
well as some transcription factors. Yet, sources of superoxide
such as the mitochondrial ETC, in the RIRR mechanisms, and
xanthine oxidase are not tightly regulated and may become
increasingly relevant in the pathology (redox stress) of I/R
injury.
III. Role of Mitochondria in Acute I/R Injury
As said, under physiological conditions, mitochondria are
the principal organelles that generate ATP. This is particularly
true for the cardiomyocytes, which are among the richest cells
inmitochondria. These organelles take also a part in a series of
metabolic processes and signaling pathways, including cell
division, and regulate cell death and life. Importantly, during
the normal heart perfusion, mitochondria consume large
amounts of O2 to produce energy with a minimal loss of
electrons to generate O2
- . They contribute to a balanced
generation and scavenging of ROS and are involved in cel-
lular ion homeostasis, including Ca2 + homeostasis. The reg-
ulation of these processes is crucial for cell function, life, and
death.
Deviation from physiological conditions may be, for in-
stance, increased mitochondrial Ca2 + concentration (calcium
overload) and increased production of ROS (oxidative stress).
Mitochondrial Ca2 + overload and oxidative stress can cul-
minate in prolonged mPTP opening and reduced synthesis of
ATP. These processes can be a part of the pathophysiology of
various cardiovascular diseases, including stroke and acute
myocardial I/R.
During ischemia, the lack of O2 inhibits the flow of elec-
trons, and the use of myocardial ATP becomes inefficient. The
proton-translocating F0F1-ATP synthase, which normally
produces ATP, goes into a reverse mode, so that it becomes an
F0F1-ATPase and consumes ATP to pump protons from the
matrix into the intermembrane space (Fig. 10). Depending on
the species and ischemic conditions, 35%–80% of ATP is
consumed by F0F1-ATPase during ischemia (124), and the
ATP is used to maintain the mitochondrial membrane po-
tential (Dwm), instead of supporting contractile function to
fuel ion pumps to maintain the cellular homeostasis of ions
such as that occurs during normal perfusion (236). This alters
ATP/AMP ratios and AMPK activation (see above). Due to
decreasing levels of ATP during ischemia, Na +/K + ATPase is
inhibited, and intracellular acidification (induced by the
production of lactate and the hydrolysis of ATP) activates the
Na +/H+ exchanger (NHE, i.e., the cell tries to restore the
intracellular pH), and the resulting increase in intracellular
Na + activates in a reverse mode the Na +/Ca2 + exchanger
(NCE), leading to Ca2 + overload. High concentration of
cytosolic Ca2 + may contribute to cell damage through the
activation of degrading enzymes such as nucleases, phos-
pholipases, and proteases, leading to the destruction of the
integrity of the membrane and cell death if the ischemic pe-
riod is long enough. The mitochondria become de-energized
at least in part, by inhibiting the Ca2 + uniporter, the major
route of entry of Ca2 + in mitochondria. However, during
prolonged cardiac ischemia, Ca2 + accumulation in mito-
chondria can occur through the reversal of the NCE (127, 128).
At the reperfusion, intracellular and mitochondrial events
such as inadequate resynthesis of ATP, oxidative stress from
ROS, low production of NO, Ca2 + overload, and loss of
membrane phospholipids contribute to reperfusion injury
(207, 208, 285) (Fig. 1). Increased concentrations of ATP via
recovered oxidative phosphorylation may contribute to the
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restoration of cellular homeostasis of ions; however, a higher
content of ATP paradoxically contributes to reperfusion in-
jury (286). In fact, in rapidly re-energized cells, Ca2 + oscilla-
tions between the sarcoplasmic reticulum and the cytosol
contribute to the hypercontraction of cardiomyocytes, dis-
ruption of themembrane, and consequent band necrosis (285–
287). In particular, it was reported that recovery of pH, Ca2 +
overload, and oxidative stress can cause the sudden opening
of the large conductance pore, mPTP, which contributes
strongly to cardiomyocyte hypercontraction, apoptosis, and
necrosis (27, 78, 81, 146, 305).
A. mPTP opening in acute I/R
Of note, mPTP opening can be temporary, intermediate, or
prolonged, depending on the complex balance between induc-
ers and antagonists (282, 283). The transient opening of mPTP is
able to generate reversible cellular changes, so that this tempo-
rary opening has been suggested to be involved in physiological
processes and cardioprotection (185). In reality, the transient
pore opening is involved in physiological events such as the
reversible intracellular trafficking of NAD+ (80), the rapid dis-
charge of excessive intramitochondrial Ca2+ (21, 171, 172), and
the transient formation of ROS (374) (see also section III.C).
Prolonged opening of the mPTP represents a key event
leading to cell death in the pathophysiology of I/R injury (337,
377). In fact, the opening of mPTP is central to the oxidative
damage associated with reperfusion. Many studies have
highlighted an important contribution of mPTP opening and
cell death that correlated with the release of Cyt c after Bax
and enhanced levels of ROS. When an mPTP is formed, mi-
tochondria are uncoupled, and ATP production is blocked,
and the matrix swells and can cause the OMM rupture (Figs. 1
and 8) [for reviews see (78, 81, 82)].
It is important to note that the probability of mPTP opening
ofmitochondria de-energized is drastically reduced belowpH
7.4, a condition that occurs during prolonged ischemia (64, 62,
112, 274). Low pH also favors the activation of both mito-
chondrial NHE and NCE, and consequently reduces the up-
take and extrusion of Ca2 + from the mitochondrial matrix
(175). Still, the low pH can also activate UCPs. These would
uncouple ATP synthesis from oxygen consumption (96).
Whether UCPs play a deleterious or protective role in toler-
ance against ischemia is controversial (24, 157). Low pH can
also inhibit glycolysis and the production of pyruvate, re-
sulting in a lower production of acetyl-CoA for the tricar-
boxylic acid cycle. Finally, this will result in a slower feeding
of the respiratory chain complexes. Therefore, low pH pre-
vents mPTP opening, mainly in ischemia.
Upon reperfusion, very different conditions are established
depending on whether or not Dwm rapidly recovers. In the
case of energized respiringmitochondria, a low pH stimulates
the uptake of Pi, raising its intramitochondrial content that
acts as a potent inducer of mPTP opening. For example, in
brain-energized mitochondria, low pH has been reported for
mPTP opening (202). In contrast, in the presence of mito-
chondrial membrane depolarization, prolonged opening of
mPTP takes place when a rapid normalization of tissue pH
occurs. This last condition (i.e., membrane depolarization and
rapid normalization of pH) is the most common scenario
during abrupt reperfusion. The mPTP opening is facilitated
by the presence of elevated levels of Ca2 + , Pi, and ROS and by
the presence of low levels of NO. In fact, when reperfusion
occurs, metabolic and biochemical changes take place in the
postischemic cardiomyocytes, including a rapid restoration of
normal pH by membrane exchangers (especially NHE), gen-
eration of ROS (including RIRR), an intracellular Ca2 + over-
load, resulting in mitochondrial dysfunction and possibly cell
death (78, 79, 286, 398). In addition to its direct action on
mitochondria, the opening effect of Ca2 + overload is also due
to indirect aspects such as swelling, band necrosis, and en-
zyme activation. For example, activation of phospholipase A2
(319), which facilitates the release of arachidonic acid from
phospholipids, and activation of calpain proteinases are both
Ca2 + dependent (325). These enzymes facilitate further mPTP
opening (Fig. 8) (175).
1. Consequences of prolonged mPTP opening. Transient
pore opening may be protective, and transient/intermediate
openingmay lead to apoptosis. Prolonged pore opening, on the
other hand, is followed by profound changes in cellular bio-
energetics that are considered irreversible. Pore opening results
in an increase inmitochondrial permeability to ions and solutes
with molecular weights up to 1500 Da, matrix swelling, loss of
electrochemical gradients, and F0F1-ATPase hydrolyses of
ATP, leading to an inevitable cell death (81, 121, 122, 127, 128).
Actually, the consequence of prolonged mPTP opening is the
collapse of mitochondrial membrane potential. This is quickly
followed by NAD+ and ATP depletion, mitochondrial release
of accumulated Ca2+ , matrix swelling, and rupture of the
OMM. The consequence may be loss of pyridine nucleotides
and release of proapoptotic factors as Cyt c, which triggers
apoptosis and thus inhibits the flow of electrons through the
ETC (21, 78, 81, 83, 128, 146, 398).
Many have suggested that the formation of long-termmPTP
is the event that leads to irreversible changes in cellular function
and death (e.g., 70 and 121). Di Lisa et al. (83) were among the
first to observe that the addition of Ca2+ causes swelling of
mitochondria and profound decreases in NAD+ content. Glo-
bal ischemia in isolated, perfused rat hearts increased by the
30% depletion of tissue NAD+ , whereas reperfusion aggra-
vated the loss of tissue NAD+ , which remains *20% of pre-
ischemic levels. Mitochondrial NAD+ levels after I/R were
only about 10%of the preischemic level (83). In particular, these
changes in tissue and mitochondrial NAD+ levels after I/R
were largely prevented by the mPTP desensitizer, CsA.
B. Prevention of prolonged mPTP opening
All these opening factors are countered by physiological
mPTP antagonists, such as adenine nucleotides (particularly
ADP), high concentrations of protons (i.e., pH below 7.4), in-
creased mitochondrial membrane potential, and magnesium
ions, as well as by physiological levels of NO (78, 372). The
pore quickly closed if Ca2 + is chelated (21, 78). The events
promoting mPTPs are prevented by some drugs (see section
X), including CsA, which is an mPTP desensitizer at nM
concentrations (12). Paradoxically, it was suggested that un-
der some conditions, Pi may be an inhibitor of mPTP. In the
absence of Pi, desensitizing effects of CsA or Cyp-D ablation
are no longer present (12).
In summary, the prolonged opening of mPTP may be one
of the key events in transition from reversible to irreversible
reperfusion injury, or cell death, during the first minutes of
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reperfusion. In fact, the opening of these channels results in a
further production of ROS and mitochondrial uncoupling of
oxidative phosphorylation and mitochondrial swelling, result-
ing in cellular apoptosis and necrosis of the myocardium. De-
spite a modest increase in the levels of Pi andmitochondrial de-
energization, Ca2+ overload, and the formation of ROS during
ischemia, the long-term opening of mPTP is antagonized by
acidosis. On the contrary, and despite an initial recovery of
Dwm, on reperfusion, mPTP opening is strongly facilitated by
pH recovery, increased matrix Ca2+ concentration, and accu-
mulation of ROS (Figs. 1 and 8). This underlines the importance
of the mPTP inhibition by acidosis in cardioprotection.
Actually, cardioprotective interventions induce several
cytosolic signaling events resulting in suppression of the
mPTP opening, but it is still uncertain how these events are
conveyed to mitochondria. It has been proposed that kinases
(e.g., PKC, PKG, and GSK-3b) may play a direct pivotal role in
the interaction with the mPTP after that these kinases are
phosphorylated by the upstream protective signals, such as
membrane receptor activation and Akt phosphorylation in
the RISK pathway (e.g., 117, 137, 141, and 185) (see section IV).
C. Transient opening of mPTP can be protective
As mentioned above, transient opening of mPTP occurs in
physiological conditions, and it can be protective (135, 308).
Transient mPTP opening has been proposed to serve as a
Ca2 + -release mechanism by which mitochondria avoid ma-
trix Ca2 + overload (170, 171, 180). It has been also proposed
that transient mPTP openings occur asynchronously in the
mitochondrial population in a stochastic fashion (198). This
may allow this population of asynchronously cycling mito-
chondria to tolerate markedly extramitochondrial Ca2 +
overload without collectively depolarizing, whereas transient
increased ROS production due to transient mPTP opening
may engage cardioprotective signaling.
A recent in vitro study (169) suggested that both transient
formation and inhibition of the mPTP can be considered for
therapeutic purposes, and that there is a defined therapeutic
window, with the first few minutes of reoxygenation being a
crucial period to achieve protection. This is the first study
describing direct transient opening of the pore as a possible
clinical target for cardioprotection in a postischemic phase. It
is necessary to confirm in future work the observations re-
ported in this study in in vivo animal models and in humans.
Thus, the emerging picture is that similar to ROS, (i) mPTP
opening is a two-edged sword, with both protective (transient
opening) and deleterious (prolonged opening) actions in both
the pre- and postischemic phases. However, this picture needs
to be supported by future in vivo studies; (ii) a more sub-
stantial picture is the one that sees the transient opening of
mPTP to be protective in the preischemic and the prolonged
opening to be deleterious in the postischemic phase. There-
fore, the pharmacological closure of the pores at this latter
stage is considered to be highly protective. These two sce-
narios are not mutually exclusive.
D. Chronic ischemia and mitochondria
Although the review focuses on acute I/R and protection,
here we will briefly consider the effects on the mitochondrial
structure and function and the possible therapeutic target in
chronic ischemia. For a more detailed insight into character-
istics of mitochondria in chronic ischemia, we kindly refer the
reader to related reviews elaborating on this point (e.g., 312).
Myocardium can respond to a prolonged decrease in
perfusion by achieving a balanced state of downregulation
of metabolic demand, termed ‘‘hibernating’’ myocardium,
which is characterized by several alterations of the mito-
chondrial structure and function. A number of small mito-
chondria within the area of reversible lesions have been
described in the myocardium chronically underperfused
(209). Two key events have been observed after acute ischemia
reperfusion and chronic ischemia. These events are the
decrease of the stimulatory effect of creatine on metabolic
activity and the increase of OMM permeability to Cyt c and
ADP. These effects indicate the alteration of the intermem-
brane space architecture, leading to the loss of intracellular
adenine nucleotide compartmentation and possibly of func-
tional coupling of mitochondrial creatine kinase and ANT.
These alterations result in the impairment of intracellular en-
ergy transfer frommitochondria to ATP-utilizing sites located
in the cytosol. This may play a significant role in ischemic
injury and alterations in the heart function (87). Preservation
of high-energy phosphate levels and reduction in MVO2 have
been observed after ischemia in chronic hibernating myocar-
dium (160). These functional alterations are usually supported
by structural alterations characterized by mitochondrial
clustering and swelling associated with membrane rupture.
Yet, favorable mitochondrial adaptations in a swine model of
chronicmyocardial ischemiahave been observed. In thismodel,
isolated mitochondria from the ischemic tissue demonstrate
preserved state-3 respiration after anoxia/reoxygenation (228).
This is consistent with a stress-resistant state, which is charac-
terized by a mild degree of uncoupling under basal conditions
and decreased O2
- generation. In fact, UCP 2 expression is
enhanced in these mitochondria, providing a potential mecha-
nism for the favorable mitochondrial adaptations (228). It may
be argued that highly localized, specific mitochondrial enzyme
changes (beneficial/detrimental) may result from chronic
myocardial ischemia, whichmaymake the differences between
surviving/hibernating or dying tissue.
Protective strategy: the transcriptional coactivator PGC-1a
coactivates downstream transcription factors such as estrogen-
related receptors, nuclear respiratory factors, and peroxisome
proliferator-activated receptors (PPARs). These factors are
known to regulate many aspects of energy metabolism, in-
cluding mitochondrial biogenesis, fatty acid oxidation, and
antioxidant detoxification (218, 312). Since PGC-1a is upstream
of the regulation of energy metabolism, targeting it may rep-
resent an approach allowing an improvement of energy me-
tabolism in multiple sites (233). Improving mitochondrial
biogenesis by upregulating PGC-1a is a strategy largely atwork
in metabolic diseases, and it has been proposed for chronic
ischemic disease. PGC-1a is regulated in a cardiac-specific
manner (233), and more work is needed to understand its role
and regulation in the normal and failing heart. Because ische-
mic disease is also a metabolic disease, such a strategy could be
beneficial in this pathology.
IV. Cardioprotective Strategies Targeting Mitochondria
in Acute I/R Injury
It is likely that the prolonged mPTP opening is the trig-
gering event in reperfusion injury. This hypothesis seems
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correct, because the observations with cardioprotective
strategies suggest that a large percentage of cell death after I/
R injury results from mPTP formation. In fact, the current
body of evidence indicates that inhibition of mPTP formation
is one of the end effectors of cardioprotective strategies (135,
137, 139, 284). The importance of mPTP closure as a target for
myocardial protection has been described in numerous in-
vestigations (e.g., 122, 137, and 184). However, as noted
above, mPTP opening and closing all the time and a transient
increase in opening probability of these pores may be in-
volved in ROS-dependent cardioprotection by PreC (138,
139). Furthermore, at least two mechanisms that are not mu-
tually exclusive have been proposed to explain the mito-
chondrial membrane permeabilization and apoptosis. Besides
mPTP, which includes the participation of both IMM and
OMM, a mechanism involving only OMM and the formation
of MAC have been described [for review see (119, 194)].
Although there is a controversy about the structure, regula-
tion, and the precise role of these two channels, strong evi-
dence indicates that the Bcl-2 family proteins contribute to
mechanisms of both mPTP and MAC formation (119, 194).
In fact, the Bcl-2 family regulates the intrinsic pathway of
apoptosis: Bax-mediated apoptosis is regulated via constant
cycling between the mitochondria and the cytosol, and ret-
rotranslocation of Bax to the cytosol depends on interaction
with Bclxl.
Mitochondria supply energy in the form of ATP. However,
mitochondria can also play a destructive role and initiate cell
death pathways. They can be the triggers and/or the final
effectors of all forms of cell death. If mitochondria play an
important role in cell death, then it is not surprising that
cardioprotective mechanisms may act, at least in part, by
opposing mitochondrial cell death pathways. Mitochondria
are both a major site for determining the loss of cell viability
and a pivotal target of processes triggered by I/R, such as
massive elevation in [Ca2 + ] and ROS events which, as said,
occur mainly at the beginning of reperfusion. In fact, lethal
reperfusion injury appears to represent from 20% to 70% of
the total amount of the irreversible myocardial damage in
experimental animals, according to the studied model and
species (175, 193, 329, 393). Also in humans, part of the car-
diomyocytes constituting the final infarct size dies after the
onset of reperfusion (223, 332, 333, 353, 384). Therefore, re-
perfusion injury limitation remains a major therapeutic target
(174, 179, 269, 368, 392). Nevertheless, it must be borne in
mind that attenuation of mitochondrial redox potential, ROS
production, and mitochondrial Ca2 + overload are also ob-
served in ischemia/hypoxia (17, 49, 191, 363–365), as we will
discuss in the next section.
A. PreC and PostC
As stated in the introduction, in 1986, Murry et al. (239)
reported that four 5-min circumflex occlusions, each sepa-
rated by 5min of reperfusion, followed by a sustained 40-min
occlusion (index ischemia = infarcting ischemia) in the dog
heart dramatically attenuated I/R injury. This phenomenon
was named PreC. In 2003, Zhao et al. (393) reported that three
episodes of 30 s of reperfusion/30 s of ischemia performed
immediately after index ischemia (60-min coronary occlusion)
in the dog heart drastically attenuated reperfusion injury. This
phenomenon was named PostC. It was soon clear that the
later the application of the first PostC ischemia, the lower the
protection (Fig. 2). The discovery of ischemic PostC provided
strong evidence supporting the existence of reperfusion injury
(154). It is commonly believed that cardioprotective signals
mediate protection by acting on the mitochondria to inhibit
mitochondrial-mediated cell death. Therefore, an under-
standing of the mechanisms of cardioprotection is strictly
linked to an understanding of the mechanisms by which mi-
tochondria regulate cell death.
The protective effects observed with PostC are comparable
to those observed with the powerful PreC (269, 393). PostC
has been shown to have salubrious effects on different tissue
typeswithin the heart (cardiomyocytes and endothelium) and
protect against various pathological processes, including ne-
crosis, apoptosis, contractile dysfunction, arrhythmias, and
microvascular injury or no reflow. The mechanisms by which
PostC alters the pathophysiology of reperfusion injury is ex-
ceedingly complex, and involves physiological mechanisms
(e.g., delaying realkalinization of tissue pH, triggering release
of autacoids, redox signaling, and opening and closing of
various channels) and molecular mechanisms (especially ac-
tivation of kinases of the RISK and SAFE pathways; see also
below) that impact on cellular and subcellular targets or
effectors (260, 367, 393).
The term ‘‘PostC’’ has highlighted the importance of in-
tervening at the beginning of myocardial reperfusion to pro-
tect the postischemic heart. This is a clinically relevant
timepoint for intervention in patients presented with AMI. As
such, its clinical application has been rapid for both STEMI
patients undergoing primary PCI (e.g., 333 and 356) and for
patients undergoing on-pump cardiac surgery (223) (see also
section XI).
Intensive investigation of the signaling pathways under-
lying PreC and PostC has identified a number of signal
transduction pathways conveying the cardioprotective signal
from the sarcolemma to the mitochondria, some of which are
common in PreC and PostC. In fact, both PreC and PostC
induce activation of signaling elements during the early re-
perfusion after the index ischemia (90) (Figs. 3 and 11). In this
phase, a great attention has been focused on the cGMP/PKG
pathway (e.g., 153, 268, and 271), on the RISK pathway (e.g.,
132, 139 and 326), which involves the kinases Akt and ERK1/
2, andmore recently, on the SAFE pathway that contributes to
PostC protection through the activation of TNF-a, its receptor
type-2, JAK, and STAT-3 (e.g., 137 and 212). All these path-
ways in PreC and PostC converge on mitochondria via the
modulation of several kinases, including GSK-3b, Bcl-2/Bax/
Bad, and PKCe (e.g., 137 and 236). In Figure 9 are reported
only the principal modalities of mitochondrial control by cy-
tosolic kinases. Nevertheless, these modalities are still con-
troversial (66, 67, 113, 296).
As said, mPTP has been shown to open at the start of re-
perfusion, and its opening is generally attributed to an over-
load of matrix Ca2 + and/or ROS increase. Therefore, it is
likely that cardioprotective signaling reduces matrix Ca2 +
and/or ROS, rather than by direct modulation of mPTP
components. However, redox signaling and acidosis in early
reperfusion are two cardioprotective processes operating in
the very early reperfusion in both PreC and PostC (Figs. 3 and
11). Therefore, these two processes may act, first, directly on
mPTP components, limiting their opening and then may ac-
tivate signaling pathways that have been suggested to
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converge again on mitochondria, definitely decreasing sus-
ceptibility to mPTP opening and mediating protection. More
details on these two processes are given in the next sections.
B. Redox signaling and acidosis in early reperfusion
Wemust consider the detrimental effects of ROSwithin the
heart, before discussing the beneficial role of redox signaling.
1. Detrimental effects of excessive ROS. Various detri-
mental processes can be the result of an imbalance between
the formation of ROS/RNS and limited antioxidant defenses
(referred to as oxidative stress). For instance, excessive reac-
tive species indiscriminately react with DNA, lipids and
proteins. These are complex processes, in brief: a radical
reaction with DNA may oxidize DNA bases such as 8-
hydroxydeoxyguanosine leading to mutation and DNA
strand breaking; reaction with lipids gives rise to peroxyl and
alkoxyl radicals, leading to lipid peroxidation; reaction with
amino acid residue side chains of proteins form protein car-
bonyls; and reaction with methionine forms methionine
sulfide (18, 362, 391, 397, 399). The lack of protection of mi-
tochondrial DNA by histones, the limited capacity of repair
mechanisms, and the proximity of mitochondrial DNA to the
production site of ROS by RIRR render the mitochondrial
DNA highly susceptible to increased oxidative stress (120,
316). Excessive oxidative stress, besides contributing to irre-
versible myocardial injury, inducing prolonged mPTP open-
ing, and leading to cellular dysfunction and cell death, may
also induce reversible injury during ischemia and during re-
perfusion (17, 206, 300, 363). As said above, oxidative stress
occurring during ischemia may be also important in re-
perfusion injury (20, 49, 364, 365). Moreover, the reversible
contractile dysfunction after myocardial I/R (stunning) is
clearly a manifestation of oxidative stress (125). Whether
stunning is due to RIRR has not been investigated yet.
ROS scavenging by administration of MPG and phenan-
throline at reperfusion reduces cell death of embryonic chick
cardiomyocytes, confirming that the burst of ROS at the onset
of reperfusion may be causal for cell death (367). In contrast,
ROS scavenging by a combination of catalase and SODduring
reperfusion did not reduce the infarct size in dog hearts
in vivo; however, microvascular injury and the low-reflow
phenomenon were attenuated (289). On the other hand, re-
perfusion plus SOD limited the myocardial infarct size in a
closed-chest pig model (244). All these contrasting results
reveal the complexity of the redox system. Moreover, low
levels of reactive species may act as secondary messengers,
modulating cardioprotective signaling pathways by a cova-
lent modification of target molecules, referred to as redox
signaling.
Therefore, the key message here is that ROS/RNS effects
may range from beneficial to reversible and even irreversible
damages mainly depending on reactive species amount,
timing, and compartmentalization.
2. Beneficial effects of redox signaling and acidosis. It
has been proposed that reintroduction of oxygen after ische-
mia induces ROS production, but it does not protect against
reperfusion injury, because mPTP opens triggering RIRR be-
fore the activation of endogenous survival pathways.
It has also been proposed that both ischemic PreC and
PostC protect, because they maintain acidosis during early
reoxygenation at the beginning of reperfusion, which inhibits
mPTP formation and allows ROS signaling, so that during
early reperfusion, acidosis and ROS signaling avoid cell death
and give the heart enough time to activate the protective
signaling pathways (e.g., RISK); thus, we can consider that the
heart preconditions itself against reperfusion injury (61, 90,
133, 135, 137, 140) (see also below). Therefore, a key event for
cardioprotection may be prolongation of cellular acidosis by
cardioprotective phenomena during early reperfusion (Figs. 3
and 11). In fact, both acidic infusion in early reperfusion or
PostC and delaying pH normalization could inhibit mPTP
during the first minutes of reflow and allow for endogenous
protective signaling pathways to be activated by a small
quantity of ROS (redox signaling). The delivery of oxygen
during acidic perfusion or the brief intermittent reperfusions
of PostC would promote mitochondrial ROS formation in a
small amount, which has been proposed to activate isoforms
of PKC (62). PKC appears as a critical kinase in the signaling
cascade, leading to a reduced probability of mPTP opening
(see below) after pH normalization (276, 388).
Hence, not only mPTP may be inhibited by redox signaling
and acidosis but also a transient opening of the mPTP has
been suggested to induce a slight, transient formation of ROS
that might be relevant for cardioprotection (21, 79, 139, 171,
282, 283). Supporting this concept, pharmacological and ge-
netic inhibition of Cyp-Dwas reported to abrogate both PreC-
induced ROS formation and protection (142, 135, 141).
We were among the first to demonstrate that the ROS
scavengers N-acetylcysteine (NAC) and MPG prevent the
protective effects of ischemic or pharmacological PostC (271,
FIG. 11. Key mechanisms proposed for PreC- and PostC-
induced decrease in susceptibility to mPTP opening during
reperfusion. Key events are transient physiological mPTP
opening in the preischemic phase and acidosis plus redox
signaling in reperfusion. These events avoid prolonged
mPTP opening, allow the activation of cardioprotection
pathways, and lead together to mPTP inhibition to the pre-
vention of cell death and organ protection. For other acro-
nyms, see the list of Abbreviations Used.
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272, 361, 382), and the same ROS scavenger has been shown to
block the protection afforded by acidic reperfusion (64, 275).
In our laboratory, isolated rat hearts were subjected to 30-min
ischemia and 120-min reperfusion, and PostC at onset of re-
perfusion by five cycles of 10-s ischemia and reperfusion each
significantly reduced the infarct size. While the protection by
PostC was lost in hearts perfused with NAC for the entire 2-h
reperfusion period, the infarct size was still reduced when, in
postconditioned hearts, the perfusion with NACwas initiated
after the first 3min of reperfusion, demonstrating an essential
role of ROS formation during early reperfusion in PostC
protection (276). Reperfusion of isolated rabbit hearts with an
acidic buffer for the first 2min of reperfusion significantly
reduces the infarct size. This cardioprotection is blocked by
co-infusion with MPG (64), suggesting the involvement of
ROS signaling in acidosis-induced protection. Infarct size re-
duction by PostC in mouse hearts in vivo was attenuated by
the ROS scavenger MPG when administered few minutes
before, but not 10min after the PostC stimulus (361). In par-
ticular, in mice, pharmacological PostC by either 1.4% iso-
flurane or 10mg/kg of the delta-opioid receptor agonist SNC-
121 was also abolished by MPG when applied immediately
before, but not 10min after reperfusion (361). NAC for the first
minutes of reperfusion also abolished PostC by bradykinin or
sevoflurane in isolated rat hearts (271). Importantly, in human
myocardium, desflurane-induced PostC was mediated by
adenosine and bradykinin receptors via a ROS signaling (214).
These data support a central role for ROS signaling during
early reperfusion in the protection by ischemic PostC and in
the protection by acidosis in early reperfusion. It is generally
thought that ROS generation at the beginning of reperfusion is
mainly mediated by an enhanced electron leak in the ETC due
to ischemic oxidative damage with an important role for the
opening of mKATP channels. It has also been suggested, and
we have obtained some data to support the concept, that
PostC might lead to increased SNO of proteins that might
protect them from oxidation (275). Indeed, acidosis may favor
NO production via breakdown of nitrite (401) and via kini-
nogenase activation and bradykinin formation, which may
activate NOS (360). Acidosis may also downregulate SOD
activity, whose optimal pH is between 7.4 and 7.8 (264). Since
SOD is a denitrosylating agent (252), acidosis may contribute
to elevation of nitrosylated proteins (275), including proteins
involved in regulation of mitochondrial energetics and cal-
cium transport (275, 340, 341; and unpublished observations
of the authors).
In summary, in protected reperfusion, low levels of ROS/
RNS might act directly on mPTP components or activate
signaling pathways that have been suggested to act on mi-
tochondria, decreasing their susceptibility to prolonged
mPTP opening. Therefore, redox signaling by transient/re-
duced formation of ROS/RNS is also included among the
triggers of PostC (274, 275).
V. Timing and Targets of ROS Signaling
in Cardioprotection
It is now clear that inhibition of mPTP opening by cardio-
protection is central for the reduction of oxidative stress. This
may be achieved by mitochondrial protein phosphorylation
as well as by the action of redox signaling. In fact, in the
context of cardioprotection, ROS/RNS with a signaling role
may play a pivotal role. ROS/RNS generated during ischemia
and/or reperfusion, in quantities below those that damage
the heart, may activate mediators that trigger cardioprotec-
tion. Therefore, protective ROS/RNS are suggested to be
formed during three time points: (i) during PreC-ischemia
and/or (ii) during reperfusion that follows the brief PreC-
ischemia, and (iii) in protected hearts, in the initial part of
reperfusion that follows the index ischemia: both (iiia) in
PostC and (iiib) in PreC context (Fig. 3).
It may be worthwhile to recall that without appropriate
PreC and PostC interventions, ROS/RNS generated at the
beginning of reperfusion are usually lethal, and not the ROS/
RNS that would trigger protection (points iiia and iiib, re-
spectively). Moreover, while ROS scavenging attenuates the
infarct size reduction by ischemic PostC or diazoxide, in-
creasing exogenous ROS formation at the onset of reperfusion
does not confer protection (271). Since pharmacological gen-
eration of endogenous ROS/RNS or administration of exog-
enous ROS/RNS (61–63, 191, 251, 262, 382, 387) before index
ischemia can trigger PreC, it is likely that the type, the con-
centration, and/or the compartmentalization of endogenous
ROS/RNS generation may play a pivotal role in triggering
protection at the reperfusion time (after index ischemia). In
fact, it must be borne in mind that both PreC and PostC may
involve different subcellular compartments that may interact,
such as the sarcoplasmic reticulum, mitochondria, and the
nucleus (135, 259, 390). Actually, the activation of Akt may
recover the impaired cardiac contractile function, induced by
the endoplasmic reticulum stress via GSK-3b-mediated sup-
pression of mPTP opening, showing a cross-talk among these
organelles (390). Moreover, while the cytoplasm is made aci-
dotic by PreC and PostC, mKATP channel opening induces
mitochondrial matrix alkalinization (66, 67, 113, 296). Finally,
while O2
-  and NO lead to ONOO - increase, ONOO - may
decrease by secondary reaction between NO and ONOO -
itself, leading to N2O3; the latter condition may occur in the
protected heart when NO formation is facilitated (275, 354).
(i) A wide body of evidence exists demonstrating that an
appreciable formation of ROS occurs during ischemia
(17, 191, 300, 334, 364, 365). In fact, mitochondrial ROS
formation is favored by a decrease in the electron flow
resulting from ETC inhibition and is counteracted by
uncoupling that is generally produced by an increased
IMM permeability to protons. Therefore, the inhibition
of ETC caused by the insufficient oxygenation facili-
tates the escape of electrons that can react directly with
the scarce available oxygen, resulting in ROS forma-
tion. A significant increase in ROS production in iso-
lated hearts during brief PreC ischemia and during the
index ischemia has been reported (191). These findings
are supported by observations in isolated cardiomyo-
cytes and other studies in the isolated perfused heart
model (17, 50, 334, 364). Therefore, it has been sug-
gested that ROS released during the brief PreC ische-
mia, and not on reperfusion, lead to activation of
cardioprotective pathways (191).
(ii) Small amounts of ROS/RNS may be formed during
reperfusion after a short period of PreC ischemia (63,
89, 140). MPG is a cell-permeant ROS scavenger that
removes OH and ONOO- very effectively and blocks
the protective effects of PreC (e.g., 67). Based on these
MITOCHONDRIA AND ROS IN CARDIOPROTECTION 21
considerations, it was tested whether the ROS/RNS
that triggers protection are produced during the is-
chemic or the reperfusion phases of the PreC maneu-
vers (89). It was concluded that protective redox
signaling occurs when molecular O2 is reintroduced
after the brief PreC ischemia, with the contribution of
transient mPTP opening (89, 140).
Nevertheless, it is not easy to solve whether are more
important ROS produced during brief PreC ischemia
or during the following reperfusion to trigger protec-
tion. It has been postulated that ROS produced during
ischemia play a role in in vitro models (236). However,
it has also been suggested that O2
- , produced during
ischemia, may be converted to downstream products
such as H2O2 and OH
 on reperfusion, and that these
species can trigger PreC (191).
(iiia) The above observations were done in the PreC
phase, that is, before the index ischemia and ex-
tended to PostC itself (142, 141). In fact, as reported
above, the PostC protective effect was abrogated by
infusing during early reperfusion a broad spectrum
of ROS scavengers, making the oxygenated perfusate
alkaline during the early reperfusion phases or
making the early reperfusion buffer hypoxic (62, 64,
111, 175, 271, 276).
(iiib) Clearly, both PreC and PostC induce activation of
signaling elements (RISK and SAFE) during the early
reperfusion after the prolonged index ischemia (90,
134, 137) (Fig. 11). It is now thought that after a
triggering phase in a preischemic period, the actual
protection by PreC occurs in the reperfusion rather
than the ischemic phase, with the repopulation of
sensitized G-protein-coupled receptor at the begin-
ning of myocardial reperfusion after the index ische-
mia (61). Hence, reintroduction of O2 at the beginning
of reperfusion permits generation of signaling ROS,
and this will activate the PKC-dependent signaling
cascade. As it has been observed for the PostC pro-
tective effect, also PreC protection was abrogated by
infusing large-spectrum ROS scavengers, making the
oxygenated perfusate alkaline or making the buffer
hypoxic during early reperfusion (61, 134, 139).
A. ROS/RNS signaling may be modulated
by antioxidants
Reactive species function as trigger molecules of protection
by activating protein kinases such as MAPK and AMPK, as
well as PKC, within and outside the mitochondria, including
PKCe (68, 72, 199, 260, 262, 270, 288, 341) and the MAPK p38
and/or JAK/STAT (387). As said, several mitochondrial
components are targeted by ROS/RNS via oxidative/ni-
trosative processes. Accordingly, many large-spectrum scav-
engers of ROS/RNS, such as ascorbic acid, MPG, or NAC,
attenuate infarct size reduction by ischemic or pharmacolog-
ical PreC or PostC, in several animal species (e.g., 109, 253, 260,
262, 269, 270, and 276). Since a target of ROS/RNS in redox
signaling is the PKC (199, 260, 288, 339, 341), the hearts can be
preconditioned by simply infusing free-radical generators
into the coronary arteries, and the resulting protection can be
blocked by either a PKC antagonist or a ROS scavenger (61,
358, 382). Evidence exists that ROS-activated PKC will also
protect the reperfused heart (262, 276). This sequence would
explain the observation that the PKC activator could rescue
hearts experiencing acidic and hypoxic reperfusion (62).
Moreover, chelerythrine, a wide-spectrum PKC antagonist,
blocks PostC protection (276, 388).
Indeed, though it has been reported that ROS/RNS can
activate kinases, and ROS/RNS scavenger may attenuate
cardioprotective pathways, recently, we have observed in an
ex vivo study that PostC and acidosis induce downregulation
of SOD, whereas catalase activity does not change in the
early reperfusion phase (275). Moreover, PostC reduces 3-
nitrotyrosine (3-NT) and increases S-nitrosylated protein
levels, thus contributing to cardioprotection triggering (275).
Indeed, in addition to activating cGMP/PKG-dependent
signaling pathways, NO/RNS can modify sulfhydryl resi-
dues of proteins through their SNO, which has emerged as an
important post-translational protein modification. Thus, SNO
of proteins is the result of a transnitrosylation reaction, or
alternatively, donors of NO + (e.g., N2O3) can nitrosylate a
cysteine moiety. SNO of mitochondrial proteins has attracted
the attention of researchers in cardioprotection (62, 64, 112,
175, 252, 274, 275). Therefore, SNO has been proposed to be
very important in both ischemic PreC and PostC cardiopro-
tection, limiting oxidative stress. As such, SNO of proteins can
be seen as a result of redox signaling, leading to a potentiation
of the antioxidant system.
B. Role of SNO in regulating mitochondrial function
in I/R and cardioprotection
Within the context of redox signaling, the increase in NO
occurring during PreC (18, 401) or PostC (173, 205, 262, 274–
276) can lead to an increase in SNO of several mitochondrial
proteins (47, 340). These are a subproteome of SNO proteins
(see below), which include complex I (47) and other proteins
involved in mitochondrial energetics, calcium transport, and
metabolism (340). Intriguingly, induction of the mitochon-
drial permeability transition by N-ethylmaleimide has been
seen to depend on secondary oxidation of critical thiol groups.
In fact, it has been reported that mPTP putative components
(see above) may have several important cysteines residues,
and that mPTP opening is blocked by low levels of N-ethyl-
maleimide (21, 79). Depending on the NO level, these cys-
teinesmay be nitrosylated and the activity of mPTP regulated.
Furthermore, SNO of proteins is rapidly reversible so
that changes would be rapidly reversed on reperfusion. It has
been reported that cardioprotection by PreC or by treat-
ment with the naturally occurring transnitrosilating agent S-
nitrosoglutathione (GSNO) resulted in an increase in SNO of
several mitochondrial proteins involved in regulation of mi-
tochondrial energetic and calcium transport, including acyl-
CoA dehydrogenase, alpha-ketoglutarate dehydrogenase,
complex I, creatine kinase, F0F1-ATPase a1 subunit, and ma-
late dehydrogenase (340). It has been also shown that PreC
results in SNO of complex I, which may result in less ROS
generation in the setting of ischemia and reperfusion (46, 47).
We have shown that also PostC results in SNO of mitochon-
drial proteins (275). For further discussion on the importance
of SNO in cardioprotection, we kindly refer the reader to
related articles elaborating on this point (e.g., 260, 274, 340,
and 341).
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VI. Preservation of Functional and Morphological
Integrity of Mitochondria by PostC
I/R and cardioprotective interventions impact on the mi-
tochondrial morphology and the intermitochondrial network,
for example, fusion and fission (254). Mitochondrial fusion
proteins include the OMM proteins mitofusin (Mfn) 1 and 2
and the IMM protein optic atrophy protein 1 (Opa1). Mi-
tochondrial fission proteins are the dynamin-related protein 1
(Drp1), which are recruited from the cytosol to the mito-
chondria, and the OMMprotein human mitochondrial fission
protein 1 (hFis1) (84). Since a Drp1 inhibitor reduces cardio-
myocyte death after I/R, decreasing mitochondrial fission is
considered cardioprotective (255). Mfn2 is localized at the
contact sites between the mitochondria and the endoplasmic
reticulum, and the deficiency in Mfn2 reduces mitochondrial
Ca2 + uptake by increasing the distance between the endo-
plasmic reticulum and the mitochondria (76). It is known that
Mfn1 and Mfn2 can each compensate to a certain degree for
the loss of the other. This may explain the absence of severe
mitochondrial dysfunctions with a loss of Mfn2; however, it
does not explain the improved recovery from ischemia and
the observed reduction in ROS. Nevertheless, the inhibition of
either mitochondrial fission or fusion limits the release of
proapoptotic factors and excessive ROS formation from
damaged mitochondria, which otherwise, may enhance
postischemic cardiomyocyte injury (76, 254, 255). On the other
hand, mitochondrial fission and fusion may be viewed as a
mitochondrial repair mechanism. In fact, irreversibly dam-
aged mitochondria are removed by mitophagy, and indeed,
the elimination of damaged mitochondria by mitophagy may
be cardioprotective (see section IX).
PreC and PostC activate cardioprotective pathways that
are protective against reperfusion injury via preservation of
functional and morphological integrity of mitochondria, even
in the postischemic phase. With regard to the PostC effect
against apoptosis, it has been suggested that it is mediated by
reduced generation of O2
- , lowered activity of JNKs/p38,
lowered levels of caspases 3 and 8, reduced release of TNF-a,
and by the modulation of the Bax/Bcl-2 ratio (338). PostC
increases the levels of antiapoptotic markers, including the
cardioprotective kinase Pim-1, decreases the proapoptotic
markers (e.g., Cyt c), and preserves the mitochondrial struc-
ture. In fact, at the onset of abrupt reperfusion, mitochondria
undergo profound structural alterations. In particular, post-
ischemic mitochondria are characterized by disruption of
membranes, broken cristae, and the appearance of dense
granules within the mitochondrial matrix, which are caused
by massive accumulation of a Ca2 + -generating insoluble cal-
cium phosphate precipitate (321). These mitochondrial dam-
ages are reduced by PostC (274). Carbonylation of
mitochondrial proteins was prevented, and aconitase activity
was preserved in the PostC hearts, suggesting that mito-
chondrial integrity was associated with a diminution in oxi-
dative stress (65).
Although PostC affects structural features of mitochondria,
it does not influence mitochondrial respiration (261). In par-
ticular, PostC does not affect basal state-4 or ADP-stimulated
state-3 respirations, excluding uncoupling or inhibition of the
respiratory chain as a mechanism of mPTP inhibition (5).
Nevertheless, while basal respiration was not affected, ADP-
stimulated respiration was increased after pharmacological
PostC with morphine (249). This last observation is in line
with many reports showing that a mild degree of mitochon-
drial dysfunction confers protection against I/R injury (e.g.,
288). It may seem paradoxical that postischemic mitochon-
drial dysfunction does not add injury, but confers protection.
In our opinion, this is the basis of the concept that cardio-
protection is afforded by a partial degree of mitochondrial
dysfunction leading to ROS signaling. In fact, when oxygen
supply is re-established after a prolonged ischemia, if some-
thing (e.g., acidosis and CsA) prevents prolonged mPTP
opening and RIRR, the partial mitochondrial dysfunction
may allow ROS signaling.
Taken as a whole, ischemic and pharmacological cardio-
protective interventions inhibit mPTP opening, prevent the
loss of mitochondrial membrane potential, allow ROS sig-
naling, preservemitochondrial morphology, and affect fission
and fusion; it is less clear whether or not PostC results in
alterations of mitochondrial respiration.
VII. Summary of PreC and PostC Pathways United
at Reperfusion
While excessive ROS/RNS formation during reperfusion,
which follows infarcting ischemia, enhances cell death, ROS/
RNS signaling during early reperfusion is essential for the
protection by ischemic and some pharmacological PreC and
PostC against reperfusion injury. As shown in Figure 3, ROS/
RNS signaling before index ischemia, that is, during brief
PreC ischemia and/or during the following reperfusion, is
clearly involved in the triggering of PreC protection. ROS/
RNS signaling is also involved in the mediation phase of PreC
and in the triggering of PostC (points iiia and iiib discussed in
the section V). Opening of mKATP channels may involve Cx43
and may be upstream of ROS/RNS signaling. Cardioprotec-
tive procedures delay the postischemic recovery of intracel-
lular pH that might prevent mPTP opening directly and
indirectly (i.e., by inhibiting calpain activation). In addition,
mPTP opening might be further prevented by a ROS/RNS
signaling that appears to depend on acidosis, which may
favor NO production and protein SNO. Redox signaling
triggers a protective kinase cascade, including PKC, and
converging on mPTP, so that mPTP closure may be depen-
dent on ROS/RNS-signaling effects, both upstream, together
acidotic effect, and downstream, depending on kinase effects.
Therefore, mitochondria are involved at least in four dif-
ferent steps to limit reperfusion injury
(i) as targets of acidosis (in terms of prevention of mPTP
opening);
(ii) as triggers or signal amplifiers (in terms of activation
of mKATP channels and the resulting formation of
small amounts of ROS);
(iii) as targets of signaling pathways and end effectors (in
terms of inhibition of mPTP opening and of release of
proapoptotic factors into the cytosol); and
(iv) as targets of damage and protection from it (in terms
of their functional and morphological integrity).
Overall, while ischemia and reperfusion damage mito-
chondria (e.g., limited oxidative phosphorylation), mito-
chondria themselves may contribute to myocardial injury
(e.g., mPTP opening-induced cell death) and protection (e.g.,
limiting mPTP opening via redox signaling).
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VIII. The Second Window of Protection
The present review mainly focuses on PostC described for
the first time by the Vinten-Johansen group (393) and on the
so-called early PreC discovered by Murry et al. (239). Early
PreC lasts 2–3 h and protects against infarction and arrhyth-
mias, but little or nothing against myocardial stunning.
However, as said in the introduction, the PreC maneuvers
also trigger a late phase of PreC 12–24 h later (Fig. 2). This late
phase is also called SWOP and lasts 3 to 4 days and protects
mainly against arrhythmias and stunning, but less against
infarction (266, 342, 348, 366). SWOP is a polygenic phe-
nomenon that requires the activation of multiple stress-
responsive genes (35, 37). Therefore, while the early PreC is
caused mainly by rapid post-translational modifications of
pre-existing proteins, the late PreC requires the synthesis of
new cardioprotective proteins, which explains the time course
of this late phenomenon, with optimal effects, 24 to 48 h after
PreC treatments (345). Actually, SWOP may be induced by
various pharmacological agents (e.g., adenosine and opioid
receptor agonists, NO donors, cytokines, and prostacyclin
derivatives) given 24 to 72 h before an infarcting I/R protocol
(37, 151). Yet, SWOP appears to be a universal response of the
heart to stress in general. Besides cytokines, SWOP can be
triggered by heat, stress, and exercise (35, 266, 323, 342, 346).
For instance, we reported that exercise-induced myocardial
ischemia may trigger an adaptive response that improves the
cardiac performance in a subsequent episode of exercise in
patients with stable angina (69).
To explain the SWOP, it has been suggested that a sublethal
ischemic stress may induce the release of chemical signals
(such as NO, ROS/RNS, and adenosine) and may trigger a
complex signaling pathway that includes the activation of
PKC, Src protein tyrosine kinases, and nuclear factor jB
(NFjB). PreC ischemias also activate JAK1/2, followed by
recruitment of STAT-1 and STAT-3. These pathways culmi-
nate in increased synthesis of aldose reductase, cycloox-
ygenase-2 (COX-2), inducible NOS (iNOS), MnSOD, and
possibly other cardioprotective proteins, which then mediate
the protective effects of SWOP (33, 35–37, 346).
The obligatory role of STAT-3 has been recently confirmed
in SWOP, using a novel inducible cardiomyocyte-restricted
STAT-3-deficient mouse. This study suggested that STAT-3
activation is important in inhibiting both the receptor path-
way and the mitochondrial pathway of apoptotic death (36).
Therefore, the protection by both early and late PreC aswell as
by PostC involves an activation of STAT-3 and is dependent
on STAT-3 levels. While the cardioprotective effect of SWOP
is clearly mediated by an increase in transcription-mediated
protein synthesis, early PreC seems independent of gene
transcription, supporting a role of STAT-3 independent of
transcriptional regulation (see also above, section II.A.3).
Common endpoints in the mechanisms of early and late
PreC have been identified at the mitochondrial level, includ-
ing the opening of mKATP channels (349) and the protection
against mPTP opening in late PreC (297, 346). This goes along
with an increased expression of Bcl-2 in the late phase. Bax/
Bak, members of the Bcl-2 family, may interact with mPTP
directly, thereby facilitating pore opening. This interaction
of Bax/Bak with mitochondria can be inhibited by Bcl-2
increases in late PreC, suggesting functional involvement of
Bcl-2 in depression of mPTP opening (297, 346). Bolli and
coworkers (311) have also studied the combination of late
PreC and PostC in a chronically instrumented rat model. The
animals underwent ischemic PreC 24 h before an infarcting
coronary occlusion and were or were not subjected to PostC
maneuvers at the onset of reperfusion after the occlusion.
Experiments were performed in the presence of the inhibition
of COX-2. These authors concluded that the combination of
late PreC and PostC produces additive protection; this is
likely due to a PostC-induced enhancement of COX-2 activity.
This is in line with our findings that protection by PostC and
bradykinin requires COX activation and prostacyclin release
during reperfusion (273). For further information on SWOP,
the reader is kindly redirected on extensive reviews on this
topic (e.g., 35, 323, 342, and 346).
IX. Autophagy and Mitophagy
Macroautophagy (called also autophagy) is a process
present in normal organs and may be involved in cardio-
protection. It is a regulated intracellular catabolic process that
serves as the quality-control mechanism of cells. Autophagy
regulates the disposal of damaged and dysfunctional protein
aggregates and organelles, including mitochondria. In fact,
the selective autophagic targeting and clearance of damaged
mitochondria is a phenomenon termed ‘‘mitophagy’’ (213).
The molecular machinery of auto- and mitophagy has been
described in several recent reviews (e.g., 85, 115, 116, 196, 290,
and 347).
It has been suggested that autophagy is essential for is-
chemic PreC-induced protection (163). These authors have
also reported that upregulation of autophagy is involved in
the cardioprotection achieved with pharmacological PreC
using different pharmacologic agents, including an adenosine
A1 receptor agonist (2-chlorocyclopentyladenosine), an
opener of mKATP channels (diazoxide), a sodium channel
blocker (ranolazine), a cytochrome P450 inhibitor (sulfaphe-
nazole), and a purinergic receptor agonist (UTP) (162, 163).
Moreover, upregulation of autophagy has been suggested to
play a causal role in the infarct-sparing effect of PostC (371).
Autophagy plays also a role in the cardioprotective mecha-
nisms developed by repetitive ischemic PreC in a swinemodel
(77). This experimental model may be more relevant to pa-
tients with chronic ischemic heart disease, who are subjected
to repetitive episodes of ischemia.
Most recently, research attention has focused on mito-
chondrial function and mitophagy. Actually, mitophagy may
be relevant to more than just PreC and PostC; it could be an
important element in lifespan extension, where periodic re-
moval of damaged mitochondria would allow their replace-
ment with new and more efficient ones (118). Moreover,
upregulation of autophagy has been associated with preser-
vation of mitochondrial membrane potential and sarcolem-
mal membrane integrity and a resultant significant delay in
the onset of irreversible cell injury (both apoptotic and ne-
crotic cell death) (222). Within the context of cardioprotection,
recent data have demonstrated that upregulation of mito-
phagy plays a pivotal role in the reduction of the infarct size
achieved with PreC (161). In transgenic mice, obtained with
genetic deletion of two molecular inhibitors of mitophagy,
p53 and TP53-induced glycolysis and apoptosis regulator
(TIGAR), it has been observed an upregulation of mitophagy.
In this model, it has been obtained a reduction of the incidence
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of apoptotic cell death and has been observed a favorable
effect on cardiac remodeling, after permanent coronary artery
ligation in vivo (159). Moreover, treatment of p53 -/ - and
TIGAR -/ - mice with chloroquine (an agent that inhibits
formation and/or degradation of autophagolysosomes) ab-
rogated the cardioprotection conferred by deletion of p53 and
TIGAR, an effect accompanied by reducedmitophagy and the
accumulation of damaged mitochondria in the ischemic
myocardium (159). These data support long-term beneficial
effects for autophagy and mitophagy in the attenuation of
adverse postinfarction left ventricular remodeling.
Taken together, these data suggest that upregulation of
autophagy and mitophagy renders myocardium resistant to
ischemic injury and may have long-term beneficial effects.
However, it has been also reported that upregulation of
autophagy in I/R is detrimental and exacerbates, rather than
limits, myocardial injury. For instance, it has been observed
that classical ischemic PreC is not associated with upregu-
lation of autophagy in the in vivo pig model (380), and that
the protective effects of PostC are accompanied by a limi-
tation in (rather than augmentation) Beclin-1 expression in
an in vitro model (88). In fact, Beclin-1 may be used as tool to
determine whether autophagy has been up- or down-
regulated by various stimuli [for review see (196)]. An in-
teresting study is that of Ma and coworkers (224), who have
shown that ALDH-2 overexpression moderates, via an
AMPK mechanism, the upregulation of autophagy in the
ischemic phase and limits autophagy, via an Akt mechanism,
in the reperfusion phase. These authors suggested that the
combination of these two actions in ischemia and reperfu-
sion may be responsible for the cardioprotective effect of
ALDH-2 against I/R injury.
The inconsistency of data on the role of autophagy may
depend onmultiple factors, includingmagnitude, timing, and
involved cell type in the process. The interconnections among
these multiple factors are at present incompletely understood.
With no doubt, as an alternative process of cardioprotection,
autophagy merits further study.
X. Comorbidities, I/R, and Cardioprotection
Before taking into account, the transition from research
laboratory to the clinic of the concept of mitochondria as the
main actors in the signals of life and death, it is worth to
discuss the changes in the mitochondrial function in some
comorbidities that can accompany the I/R in humans. In fact,
ischemic heart disease in humans is a complex disorder
caused by or associated with known cardiovascular risk fac-
tors, including aging, hypertension, myocardial hypertrophy,
and/or MS (i.e., obesity, hyperlipidemia and diabetes). These
conditions may be confounders in the outcome of cardio-
protection. Moreover, although not a comorbidity, sexmay be
a complicating factor: in different animal models, the mag-
nitude of I/R injury seems reduced, but the cardioprotection
of conditioning stimuli seems attenuated in adult females
versus males (104, 152, 235, 269, 277).
A. Mitochondria and MS
Since the MS is an archetypal condition with an altered
mitochondrial function, and since it has an increasing preva-
lence in the patients with ischemic cardiovascular disease (97),
this condition will be considered with more details. Other risk
factors of heart diseases are briefly discussed; for further de-
tails, the reader may see (104, 259, 368).
MS is now defined as a complex syndrome, which includes
several interrelated disturbances of glucose and lipid ho-
meostasis, which may lead to diabetes (108). Since the MS
induces a significant variation of O2 consumption, alterations
in the mitochondrial function andmitochondrial morphology
play a major role in this syndrome (43). Several studies as-
sociated mitochondrial dysfunction and the MS; for example,
Wisløff et al. (377) proposed an association between low ex-
pression of the protein involved in mitochondrial function, in
the skeletal muscle, with the occurrence of multiple cardio-
vascular risk factors (insulin resistance, hyperlipidemia, and
hypertension) in rats with low oxidative capacity. In humans,
for instance, Peterson et al. (281) found that the increase in
Body Mass Index was associated with an increase in myo-
cardial VO2, reduced cardiac efficiency (ratio of cardiac work
to VO2), and impaired glucose tolerance correlating with
increased fatty acid utilization. A reduced cardiac phospho-
creatine/ATP ratio, an impaired high-energy phosphate me-
tabolism, and a cardiac energy deficit have been reported
(314).
In diabetic and obese individuals, the increasedmyocardial
fatty acid oxidative capacities aremediated, at least in part, by
increased activity of PPARs (43), which are regulators of fatty
acid oxidation in the heart. In particular, PPARa increases the
expression of genes involved in several steps of cardiac fatty
acid utilization (11). It has been reported that either high-fat
diet or streptozotocin-induced diabetes may increase UCP
expression in the striated muscles (54, 187). This increased
expression may play a pivotal role in supporting increased
oxidative stress. Moreover, type-2 diabetes patients have been
shown to possess reduced ETC capacities and reduced citrate
synthase activity (189, 316). The preferential metabolism of
fatty acids, reducing glucose utilization (280), causes gradual
dysfunction of pancreatic beta and other cells and upregula-
tion of mitochondrial UCP2 and UCP3, thus resulting in an
increased uncoupling of mitochondrial respiration, a reduced
ETC activity, and ATP production, with subsequent skeletal
muscle fatigue (126, 317). Whether this occurs in the myo-
cardium is not clear. Preferential metabolism of fatty acids
and reduced glucose utilization correlate with the reduced
muscle ETC activity (189) andwith the decreasedwhole-body
anaerobic capacity (315). Studies demonstrated disparate ef-
fects of oxidative stress on mitochondria and implicated oxi-
dative stress as a cause of mitochondrial dysfunction in
diabetic hearts (Fig. 12).
The low levels of O2
-  and H2O2 normally produced by
mitochondria are overproduced in MS and associated dis-
eases (219, 316, 317). In fact, in MS and diabetes, ROS may be
predominantly derived from mitochondria as opposed to
cytosolic origin. As described above (Fig. 5), excess O2
-  can
(i) directly damage iron–sulfur center-containing enzymes, (ii)
be converted to H2O2 (and ultimately to OH
), and (iii) react
with NO to produce ONOO - , a potentially dangerous RNS
(19). As said above, fatty acids are particularly sensitive to
ROS/RNS oxidation, resulting in the formation of lipid per-
oxides, which are cytotoxic and lead to free-radical damage of
other lipids, proteins, and DNA, especially mitochondrial
DNA (119, 316). Even before the diagnosis of MS or type-2
diabetes, the accumulation of oxidized fatty acids in mito-
chondria can result in a progressive oxidative damage. In fact,
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continually excessive ROS production by mitochondria has a
role in the development and progression of diabetes and its
complications, including cardiac pathologies.
Mitochondrial proteome changes with diabetes types 1 and
2 (38, 320). Moreover, MS and diabetes are also associated
with alterations in kinase phosphorylation, in particular in
ERK1/2 and Akt phosphorylation, possibly due to alteration
in phosphatase activity (164, 166, 293, 359, 368).
Taken together, in diabetes and MS, in general, altered
mitochondrial substrate flux, increased activation of UCPs,
reduced activation of kinases, and excessive ROS/RNS pro-
duction may play important roles in the development and
progression of the disease and in contributing to cardiac
dysfunction (Fig. 12). Thus, novel treatments that are targeted
to these alterations might lead to new therapeutic approaches
for the prevention of cardiac dysfunction.
1. Cardioprotection in MS. In support of the importance
of the oxidative stress in diabetic cardiomyopathy, Shen et al.
(320) have reported that protection of both cardiac function
and mitochondria can be induced by overexpression of
MnSOD. These authors also reported that morphological al-
terations (broken mitochondrial membrane, mottled matrix,
and swelling) and the increase in mitochondrial biogenesis
could be observed and reversed as well. Also, AMPK inacti-
vation has been linked to diabetes and MS in general. For
instance, genetic ablation of the AMPK a2-catalytic subunit in
murine models led to a phenotype of MS (370). Moreover, as
said above, glucose metabolism during myocardial ischemia
appears to be affected by impairment of AMPK in the heart
(51, 53). Therefore, it has been proposed that modulation of
AMPK activity in the diabetic heart may overcome the in-
creased susceptibility to I/R injury (263).
In multiple models of either type 2 diabetes or MS (e.g., db/
dbmice, WOKW, Goto-Kakizaki, or Zucker-fatty rats), and in
streptozotocin-induced type 1 diabetes, cardioprotection
achieved with ischemic or pharmacological PreC is either
absent (123, 190, 203, 350) or markedly attenuated (359). It has
been also observed that an augmented stimulus may be re-
quired to achieve the threshold for a critical level of Akt
phosphorylation and cardioprotection in diabetic rat hearts
(359). Of note, during the initial development of experimen-
tally induced type 1 diabetes, the heart is more resistant to I/R
injury (104).
Also, ischemic PostC is ineffective in limiting I/R injury (39,
293) and may even increase the infarct size in the presence of
diabetes (284). Similar negative findings have been obtained
with pharmacological PostC with anesthetics (iso- and sevo-
flurane) (165, 298). Intriguingly, direct targeting of the mPTP
with CsA has been shown to restore the protective effects of
sevoflurane (165, 298), thus suggesting that alteration in sig-
naling associated with hyperglycemia may be mainly located
to upstream components of the cardioprotective pathways.
Nevertheless, a direct targeting of mPTP is not always effec-
tive to restore PostC protection (164). Another strategy that re-
established the protective effects of PostC was the normali-
zation of blood insulin and glucose levels via islet cell trans-
plantation (284). These findings are important, as they imply
that signaling andmitochondrial defects in diabetic hearts are
potentially reversible.
B. Cardioprotection in Aging
Clearly, the cardioprotective effect of PreC and PostC and
pharmacological conditioning decrease with aging (1–3, 25,
30, 292).
Oxidative stress is considered causal for the process of
aging (330, 375). Aging cardiomyocytes are subjected to en-
hanced ROS production, which damages mitochondria, re-
duces mitochondrial fission, and contributes to the formation
of larger mitochondria (351, 375). These giant mitochondria
are not effectively removed by mitophagy, and therefore ac-
cumulate within cells. They often contain mutated DNA and
altered proteins of the respiratory chain, and therefore con-
tribute to excessive ROS formation and further oxidative
protein damage (330, 351, 375).
Age and associated comorbidities are characterized by
changes in the expression and activity of typical cardiopro-
tective signaling proteins (e.g., ERK1/2, PI3K-Akt, STAT-3,
p38 MAPKs, and PKCs), both under baseline conditions and
in response to stressors such as I/R (123, 168, 200, 201, 242). It
is not yet clear if any of this variability in response originates
at the mitochondrial level. However, it has been suggested
that Cx43 and STAT-3 are reduced not only in ventricular total
protein extracts but also in mitochondria isolated from aged
mice (28, 30). Moreover, the amounts of nuclear encoded
mitochondrial proteins are also affected by age and associated
diseases. These include proteins involved in ATP synthesis
and mitochondrial respiration, as well as STAT-3 and Cx43,
which are considered important for cardioprotection (24, 31,
32). In fact, with aging the transcription of genes encoding
proteins with different functions, including those of ETC (23),
is reduced, thus contributing to the development of mito-
chondrial dysfunction (27).
A decreased level of STAT-3 in aged hearts may affect the
expression level of STAT-3-target genes. Indeed, the expres-
sion of MnSOD is decreased in aged rat hearts (105). How-
ever, in mice, mRNA and protein levels of the STAT-3-target
iNOS are elevated with age (14, 381). It is likely that increased
levels of TNF-a in aged mouse hearts may contribute to
the enhanced transcription of iNOS via enhanced O2
-  for-
mation and subsequent NFjB activation (14). Since the
FIG. 12. Main alterations leading to mitochondrial and
cardiac dysfunction in metabolic syndrome (MS). MS is
considered as one of the archetypal conditions that may alter
mitochondrial function, thus compromising the possibility to
induce cardioprotection. For other acronyms, see the list of
Abbreviations Used.
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cardioprotection by SWOP and pharmacological PreC is de-
pendent on iNOS (35, 265), the enhanced iNOS levels may
contribute to the preservation of SWOP in aged hearts.
On the whole, in aging, there is an increased susceptibility
to I/R, which is likely due to enhanced oxidative stress (31,
330, 351). Moreover, ischemic PreC and PostC lose their ef-
fectiveness. The mechanisms responsible for the loss of pro-
tection in the aged heart include alterations in gene/protein
expression, signal transduction cascades, and altered mito-
chondrial function (e.g., ROS formation and respiration).
However, some contrasting results are reported; for ex-
ample, a limitation of I/R injury with PreC has been reported
in rabbits aged 2–4 years (227, 291) and in sheep aged 5–8 year
(45); rats aged 16–18 months did not lose the possibility to
protect the heart with ischemic or pharmacological PostC
(323, 385). We cannot rule out that an inappropriate defini-
tion of aged cohorts may explain some of these discrepant
findings. In fact, we should keep in mind that aging is a
continuum; thus, a temporal phase of adaptability in cardio-
protective signaling, including alternative mediators or sig-
naling pathways, may explain some positive results inmodels
of initial aging (291). In this regard, prolonged, preischemic
administration of opioids, as well as caloric restriction and
exercise, has been seen to contribute to adaptations that pre-
vent the age-induced loss of cardioprotection (1, 2, 256).
C. Cardioprotection in hypertension and hypertrophy
Left ventricular hypertrophy as a consequence of sustained
elevation of cardiac work load is an important form of cardiac
remodeling, which occurs in many pathological conditions,
among which arterial hypertension is the most common.
There is experimental evidence that hypertrophied myocar-
dium is at a greater risk of sustaining injury after I/R [for
review see (104)]. However, there are few studies in hyper-
tensive animals with infarct size as the principal end-point,
and these studies have not clearly demonstrated an increased
infarct size in the hypertrophied heart (93, 104, 278). Never-
theless, several biochemical and metabolic alterations have
been observed in the hypertrophic myocardium. These in-
clude altered mitochondrial energetics and ATP production
and alterations in glycolytic metabolism with lactate accu-
mulation during ischemia (4, 250, 257). Moreover, increased
ROS generation and reduced antioxidant potential have been
described (13). Although these data have not been consistent,
they may explain the increased sensitivity of hypertrophied
myocardium to I/R injury (104).
The cardioprotective effect of pharmacological PreC is
blunted inmodels of hypertension and hypertrophy. Yet from
studies on ischemic PreC, it seems that the protection is con-
served in the early stages of hypertrophy and lost as hyper-
trophy increases (92, 93, 104). Interestingly, initial reports also
suggest that the beneficial effects of PostC are largely main-
tained in models of hypertension and/or hypertrophy (103,
215, 278, 394). Among the studies in which the infarct size was
assessed, one has demonstrated robust, PostC-induced car-
dioprotection in a mouse model of transverse aortic con-
striction via the ERK1/2 pathway (215); another study has
shown that PostC protects remodeled hypertrophic myocar-
dium via the PI3K-PKB/Akt pathway (394). We observed a
nonsignificant trend toward reduction of infarct size with
PostC in spontaneously hypertensive rats (278). Moreover, in
this study, we have shown that protection by PostC cannot be
added to the beneficial effects of antihypertensive therapy
with captopril. In other studies (267, 279), we have shown that
during nandrolone treatment, which induces a progressive
myocardial hypertrophy, the efficacy of ischemic PostC was
preserved or even enhanced in a not-yet hypertrophic heart;
this is reminiscent of the supernormal period (with increased
resistance to I/R) observed during experimental diabetes
development. However, the protective efficacy of PostC was
lost in hearts clearly hypertrophic. In this study, we have
shown that the levels of survival kinases change during hy-
pertrophy development (279).
Whether infarct size reduction with ischemic PreC and
PostC is, indeed, preserved in hypertension and/or hyper-
trophic myocardium remains to be substantiated in future
studies. Moreover, the possible alterations of the cardiopro-
tective pathways, especially those of PostC, in the hypertro-
phic/hypertensive heart need to be further studied.
XI. Transition to the Clinical Setting
PreC with ischemia (including remote PreC) or drugs may
be applied in planned interventions in the clinical arena.
However, PreC is not always feasible, because the occurrence
of AMI is hardly predictable. Instead, ischemic PostC appears
to be feasible in the majority of patients, including STEMI
patients with AMI. PostC, that is, brief episodes of ischemia
and reperfusion can be performed at the time of reflow during
PCI or direct stenting. In fact, the PostC stimulus applied in
such a patient with AMI using inflation and deflation of an-
gioplasty balloon after reopening of coronary artery reduced
the infarct size (333, 356). Therefore, PostC transition to the
clinical setting has proven the existence of lethal myocardial
reperfusion injury inman, and the clinical studies suggest that
40%–50% of the final reperfused infarct in humans may be
attributable to myocardial reperfusion injury (384). In an
original study, the investigators evaluated the level of oxi-
dative stress associated with reperfusion in patients under-
going PCI and ischemic PostC (225). Malondialdehyde, a
nonspecific marker of lipid peroxidation, was measured in
blood several times during the first 7 days of reperfusion. The
level of malondialdehyde was significantly lower in the
postconditioned than in the control patients, suggesting that a
part of the beneficial effect of PostC could be explained by a
reduction in oxidative stress (225), as shown in experimental
studies (339, 393). Moreover, PostC has been effectively used
in several settings, including before removal of aortic cross-
clamping after cardiac surgery (223).
However, two recent studies (111, 332) using the estab-
lished ischemic PostC algorithm of four cycles of 1-min re-
occlusion/reperfusion found no protection in terms of either
creatin kinase and troponin release or infarct size measure-
ment by magnetic resonance imaging. Therefore, in humans
as well as in experimental animals, there are both several
positive and a few negative studies with ischemic PostC (154,
327).
A. The possible reasons of variable outcomes
with ischemic PostC
In our opinion, it is not surprising that a variability (ranging
from highly protective to negative results) in themagnitude of
myocardial salvage can be observed among some clinical and
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experimental studies. Both the I/R injury and the PostC
protection may be influenced by a plethora of conditions that
is not easy to keep under the control of the operators (physi-
cians, cardiologists, and researchers), especially in the clinical
arena. Particularly relevant are the variables correlated to
artery reopening. For example, in determining whether I/R
injury may be relevant whether or not the artery is fully reo-
pened. This is also relevant in determining PostC cardiopro-
tection: an artery not completely reopened in the I/R setting
(control group)may exert a sort of gentle reperfusion thatmay
reduce the infarct size, thus restricting the difference with
hearts protected by ischemic PostC (stuttering reperfusion in
the treatment group). On the other hand, an artery not com-
pletely reopened during PostC maneuvers may reduce car-
dioprotective effects, thus further restricting the difference
with hearts treated with full reperfusion only. Many of the
negative studies with PostC did not check whether or not the
artery was fully reopened during the stuttering reperfusion
(PostC maneuvers). Moreover, as said above, factors that are
known to influence/limit the cardioprotective benefits of both
PreC and PostC include age, gender, and the use of drugs (e.g.,
46, 161, 235, 277, and 350). In fact, a number of medications
can limit I/R injury, including ACE inhibitors, adenosine,
AT1-blockers, statins, b-blockers, dronedarone, ivabradine,
and nitroglycerine (60, 149, 150, 272, 278, 327). Moreover,
drugs such as COX inhibitors can interfere with PostC
molecular mechanisms (273). Therefore, it is not only the at-
tenuation of protection in the PostC cohort but also the po-
tential recruitment of protection in the control group, which
may minimize any difference between PostC and control.
Moreover, another possible confounder is the presence of
comorbidities (MS, diabetes and hyperlipidemia, and hyper-
tension), including increased age, which are all risk factors for
cardiovascular diseases (see above). In fact, patients exhibit-
ing one or more of these risk factors are the actual populations
in which the incidence of AMI is greatest, and thus cardio-
protection is required (104, 221).
Therefore, due to the complexity of alterations in the
presence of comorbidities and due to complexity and vari-
ability of ischemic PostC responses, this procedure will be
translated to a clinical routine only when the signaling path-
way is fully understood. Moreover, we need to understand
the reasons for the incongruity between experimental models
and clinical outcome, especially in the settings with co-
morbidities. In fact, it seems that the majority of comorbidities
limit cardioprotection in the experimental setting, whereas
comorbidities do not appear as a major problem in a clinical
setting (179, 284, 333, 353). How can this discrepancy be rec-
onciled? One difference may be due to the fact that humans
with comorbidities are receiving adequate treatments. There
are encouraging clinical data suggesting that patients with
AMI may benefit from preserved mitochondrial function,
thereby emphasizing the paramount importance of mito-
chondria as therapeutic targets to limit I/R injury. The bene-
ficial effects are obtained despite an important incidence of
comorbidities in these patients.
B. Pharmacological PostC
Since mPTP is a major factor in determining cell death and
is considered one final step in cardioprotective signaling
cascade, mPTP inhibition affords significant cardioprotection
(10, 81, 127, 142); in fact, this concept has been successfully
translated into clinical practice (e.g., 179 and 284). Yet, ische-
mic PostC may be limited to angioplasty and surgery, and
may be associated with increased complications of the oper-
ative procedure, and thus the most constructive strategy
would be pharmacological PostC.
Pharmacological PostC would avoid the unfavorable con-
sequences linked with intermittent artery cross-clamping and
provide a simple method of myocardial protection subse-
quent to all cardiac procedures, including coronary reopening
with thrombolytics (384). However, caution must be used; in
fact, previous attempts to intervene at the onset of reperfusion
using pharmacological agents as a strategy for protecting
against myocardial reperfusion injury have been extensively
investigated, and in terms of translation, the treatment strat-
egy into clinical therapy has been largely disappointing (33,
384). For instance, adenosine has been considered for long
time as the ideal candidate for protection against I/R damage,
based on several experimental evidence of its protective ef-
fects, which however did not solve the conundrum of effective
receptors: adenosine has at least four receptors that can
change their affinity for the agonist at different times of is-
chemia and reperfusion, and at present, it is unclear which
ones of the different receptors are more important at different
stages (60, 61, 368). Despite intensive investigation with
adenosine and specific receptor agonists, it is difficult to
conclude as to a protective role of adenosine in STEMI pa-
tients (179, 303). Glucagon-like peptide-1 is another drug that
has been demonstrated to improve the left ventricular ejection
fraction by about 35% in patients with severely reduced left
ventricular function after AMI (245), but the study was not
designed to reduce lethal reperfusion injury, as the drug was
administered several hours after reperfusion, that is, far from
the therapeutic window for reperfusion injury. However,
initial progress has been made with more novel approaches
for preventing myocardial reperfusion injury administering
the drug in the first minutes of reperfusion (135). As said,
preliminary clinical data indicate that drugs targeting mPTP
or RISKs may confer benefits to patients with AMI, with and
without comorbidities, increasing that provided by myocar-
dial reperfusion alone. Very good results are obtained with
drugs such as CsA as an mPTP desensitizer (230, 284, 333), as
well as with other drugs targeting RISKs, such as erythro-
poietin and its analogs (e.g., 22 and 44). Moreover, the pro-
tective effects of the KATP channel opener, nicorandil, on the
one hand, and natriuretic peptide, on the other hand, were
studied in J-WIND trials (195). Treatment with a natriuretic
peptide was associated with a small but significant reduction
in the infarct size and improvement in the ejection fraction,
corresponding to a better clinical outcome. In this study, ni-
corandil did not affect the size of infarct size, though oral
administration of nicorandil during follow-up increased the
left ventricular ejection. In another small study, a dose of ni-
corandil that was three times higher than that used in J-WIND
decreased the infarct size and reduced re-admission to hos-
pital for chronic heart failure or the rate of cardiovascular
death in patients with AMI (178).
The treatment with CsA in the setting of AMI in conjunc-
tion with reperfusion therapy was safe and significantly re-
duced the size of the infarction (179). In a follow-up study,
Mewton et al. (230) recently examined whether CsA might
have modified LV remodeling in that subgroup of patients
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with appreciable effects on the infarct size. The authors de-
scribed that a reduction persisted after 6 months, and that
CsA did not exert any deleterious effect on LV remodeling.
Importantly, similar cardioprotective effects were obtained
with other drugs acting on mPTP, confirming the relevance of
this approach. For instance, derivatives of CsA, such as [N-
methyl-ala6]CsA, [N-methyl-Val4]CsA, Debio 025, NIM811,
or sanglifehrin A (126–128, 133, 134, 136–139, 141, 142, 230),
also prevent myocardial I/R injury in an experimental setting.
TRO40303 is a new drug that inhibits mPTP triggered by
oxidative stress. Its efficacy in an animal model of AMImakes
TRO40303 a promising new drug for the reduction of myo-
cardial I/R injury, which acts on mitochondrial translocator
protein 18 kDa (TSPO) at the cholesterol site. TSPO is a five-
transmembrane-domain protein that is localized primarily in
the OMM, and it is involved in the translocation of cholesterol
from the OMM to the IMM. Since TRO40303 binds to the
TSPO, its mode of action differs from that of other mPTP
desensitizer, such as CsA, thus providing a new promising
pharmacological approach to studymPTP regulation (313). In
our opinion, a fortunate aspect of these drugs is that they are
not inhibitors, but desensitizers, which do not abolish ROS
production in any cellular conditions, but only inhibits it,
thus, might not interfere with the protective redox signaling.
One molecule that has received much attention is nitrite
(NO2
- ) (324). A strong debate surrounds the mechanisms of
nitrite-mediated cardioprotection, with a central focus on the
identification of the nitrite reductase responsible for the bio-
transformation of this molecule in hypoxia. Candidates for
this activity include deoxyhemoglobin, deoxymyoglobin, and
various components of the respiratory chain itself. In addi-
tion, the mechanism by which the hypoxic metabolites of ni-
trite bring about protected phenotype is also matter of
controversy, but interestingly, it is thought that mPTP, ROS-
modulation, and SNO of proteins may play a role (306, 309).
Notably, regardless of these mechanisms, nitrite is now en-
tering clinical trials for AMI. Much attention in the cardio-
protection field has also focused on the effects of volatile
anesthetics, which are largely shown to be cardioprotective in
many species, including humans (130, 165, 214, 298, 336). It
has been shown that some of these anesthetics can inhibit
mitochondrial respiration, whereas others are thought to ac-
tivate K+ channels in the mitochondrial membrane (214, 336).
Yet, irrespective of the exact mechanism, anesthetics currently
represent one of the most widely used, safest, and most clin-
ically applicable cardioprotective agents.
C. Features of a successful cardioprotective approach
in early reperfusion
Due to the abundance of mitochondria in cardiomyocytes
and to the compelling dependence of myocardial function on
oxidative phosphorylation, it is hardly surprising that treat-
ments targeting these organelles are successful in myocardial
cardioprotective interventions. Besides the more appropriate
target (mitochondrial elements) reached by the drugs, it is
likely that novel approaches can achieve more success, be-
cause the essential factors are understood and considered
recently. First of all, the time window for ischemic PostC is a
critical factor (193, 269, 270). In fact, during angioplasty, the
treatment (either ischemic or pharmacological PostC) should
be applied before (drugs) orwithin the first minute after direct
stenting of the culprit coronary artery. Several other major
confounding factors that have been shown to deeply influence
the results of all infarct size reduction studies must be taken
into consideration, including the timing of the protective in-
tervention with respect to reflow and the major determinants
of infarct size (duration of ischemia, size of the area at risk,
collateral circulation, and microembolic complications) (147).
Besides the phosphorylation, also the redox signaling, the
SNO and the other forms of signaling in the early reperfusion
should be borne in mind for a successful treatment in re-
perfusion. The disappointing results with antioxidants may
be due, at least in part, to limitation of protective ROS in the
very early phase of reperfusion (260). The possibility also
exists that intermittent treatment might be helpful (271–273).
In fact, we have shown that brief repetitive (intermittent)
administration of bradykinin during early reperfusion can
trigger PostC through a redox signaling (271). Finally, Cohen
et al. (64) have highlighted the fact that staccato reperfusion
reintroduces intermittent reoxygenation to perpetuate myo-
cardial acidosis and to initiate protection.
Therefore, a pharmacological approach in the very early
phase of reperfusion, which targets mitochondria, allows a
ROS signaling, and preserves acidosis, may represent an im-
portant goal for strategies protecting ischemic–reperfused
myocardium. Of course, the presence of comorbidities and
drugs already used by the patient must be considered and
targets adjusted accordingly.
XII. Executive Summary and Conclusions
It appears that many different signals can target mito-
chondria and can induce mPTP formation, strictly linking I/R
stress and damage to these organelles. This emphasizes the
capacity of mitochondria to function as general cell-death
sensors and to integrate many lethal signals.
ROS production increases during ischemia until the O2 is
exhausted; then, it may further increase in early reperfusion
(17, 89, 191, 220, 396, 401). In ischemic hearts, the pH falls to
6.8 or less, but abruptly rises with reperfusion. Recovery of
pH is due to the action of membrane exchangers and to H +
washout of the previously ischemic cells by restored blood
flow. Formation of mPTP is limited during ischemia by the
lowpHdespite increased cellular levels of ROS andCa2 + (Fig.
1A). However, as pH returns to its baseline level and ROS
formation increases, mPTP opens; therefore, ROS production
is hastened by RIRR; mitochondrial electrochemical gradients
are disrupted; ATP production is halted; and the cell is tar-
geted for apoptosis and necrosis (Fig. 1B).
In the protected hearts, slightly/slow pH changes during
reperfusion are suggested. In particular, elaborate signaling
during the brief PreC and PostC ischemia is triggered, in-
cluding small ROS formation with an important redox-
signaling role (Fig. 3). In reperfusion, as soon as flow and O2
are restored to the myocardium, a huge production of dele-
terious ROS may occur. However, slight production of ROS
and a slower recovery of pH may occur in preconditioned
hearts, which together with other endogenous protagonists
lead to prevention of mPTP opening. In postconditioned
hearts, the repeated brief coronary reocclusions keep the pH
low enough to inhibit mPTP opening at the onset of reperfu-
sion. In the meantime, the intermittent reoxygenation permits
only a low amount of ROS with an important signaling role.
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This provides time for the signaling to generate those en-
dogenous inhibitors of mPTP formation that keep the pores
from opening even after return of pH to the baseline value.
Yet, after a triggering phase in the preischemic period, the
actual protection by PreC occurs in the reperfusion rather than
in the ischemic phase with the repopulation of sensitized
GPCR at the beginning of myocardial reperfusion after the
index ischemia (i.e., a possible sensitization of relevant re-
ceptors is induced by prior ischemias). GPCR agonists include
adenosine, bradykinin, and opioids. The exact subtypes of
adenosine, opioids, and bradykinin receptors involved in
triggering protection are still a matter of controversy. Re-
ceptor tyrosine kinases may be also involved, possibly via the
EGF receptor transactivation to activate PI3K/Akt, so that
after release/accumulation of ligand(s), GPCR-respective re-
ceptor engagement leads to activation of both ERK1/2, and to
activation of the PI3K/Akt cassette. Both PreC and PostC
engage GPCR and enzymes (Akt, AMPK, PKC, GSK-3b, etc.),
which converge on the mPTP. Importantly, PKC can be acti-
vated by (i) Akt signaling, (ii) phospholipase signaling, (iii)
ROS signaling, and (iv) cGMP/PKG pathway. The latter may
start from activated Akt, which can phosphorylate multiple
substrates, including eNOS, which activate the PKG path via
elevated NO/cGMP, both in PreC and PostC. Thus, both
PreC and PostC activate cardioprotective pathways that are
protective against reperfusion injury. Another prosurvival
factor activated in response to TNF receptors binding is the
JAK/STAT-3 pathway (Fig. 9). A cross-talk between this
pathway and the Akt pathway may exist. All these signal
transsduction pathways then terminate on mitochondria,
regulating mitochondrial function and keeping mPTP close.
As said, the closure of the mPTP is also due to the acidosis, in
the early stages of reperfusion. Autophagy andmitophagy are
other mechanisms that may influence the outcome of cardi-
oprotection.
Several proof-of-concept clinical studies on ischemic and
pharmacological PostC tested ischemic PostC at the begin-
ning of angioplasty or direct stenting, as well as pharmaco-
logical PostC. Indeed, some of these studies demonstrated
beneficial effects of the mPTP desensitizer CsA during early
reperfusion in patients with AMI (179, 230, 333). These are
relatively safe and relatively easy-to-perform procedures, and
might induce a persistent reduction in the infarct size and
improvement in myocardial contractile function (333, 356).
However, a couple of small clinical studies have obtained
negative results with PostC (150). Nevertheless, the question
of whether these treatments improve clinical outcomes has
not been assessed yet in clinical trials, including a large-scale,
multicenter, controlled, randomized study with multiple pa-
tients’ stratification. Such studies to determine the impact of
ischemic and pharmacological PostC on patient outcomes are
mandatory. Moreover, since mitochondria and ROS are at-
tractive mechanistic targets for cardioprotection, much at-
tention should be devoted to the critical points above
considered (confounding comorbidities, co-medications,
problems with interventional procedures and artery reopen-
ing, timing of the interventions, redox signaling, etc.). Perso-
nalized therapies directed to either prevent mPTP formation
or the events leading to mPTP opening might be achievable in
the future. Although we have made enormous progresses in
the treatment of cardiac ischemia, there remains a need for
innovative treatments to further decrease the morbidity and
mortality. In the AMI patients, a pharmacological approach in
the very early phase of reperfusion that (i) targets mPTP, (ii)
allows a ROS signaling, and (iii) preserves early acidosis
needs to be tested.
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Abbreviations Used
Dwm¼mitochondrial membrane potential
AICAR¼ aminoimidazole carboxamide
ribonucleotide
AIF¼ apoptosis-inducing factor
ALDH¼ aldehyde dehydrogenase
AMI¼ acute myocardial infarction
AMPK¼AMP-activated protein kinase
ANT¼ adenine nucleotide transporter
APAF1¼ apoptotic peptidase-activating factor 1
ATP¼ adenosine triphosphate
Bcl-2¼B-cell lymphoma-2
cGMP¼ cyclic guanosine monophosphate
COX¼ cyclooxygenase
CsA¼ cyclosporine A
Cx43¼ connexin-43
Cyp-D¼ cyclophilin D
Cyt c¼ cytochrome c
DAG¼diacylglycerol
DDP¼deafness dystonia protein
Drp1¼dynamin-related protein 1
eNOS¼ endothelial nitric oxide synthase
ERK¼ extracellular signal-regulated kinase
ETC¼ electron transport chain
GSK¼ glycogen synthase kinase
GSNO¼ S-nitrosoglutathione
H2O2¼hydrogen peroxide
HKs¼hexokinases
HNE¼ 4-hydroxynonenal
Hsp90¼heat shock protein 90
IAPs¼ inhibitor of apoptosis proteins
IMM¼ inner mitochondrial membrane
iNOS¼ inducible nitric oxide synthase
I/R¼ ischemia/reperfusion
JAK¼ Janus kinase
KATP¼ATP-sensitive potassium channels
KO¼ knockout
MAC¼mitochondrial apoptosis-induced
channel
MAOs¼monoamine oxidases
MAPK¼mitogen-activated protein kinase
mCx43¼mitochondrial Cx43
Mfn¼mitofusin
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Abbreviations Used (Cont.)
mKATP¼mitochondrial ATP-sensitive potassium
channels
MnSOD¼manganese superoxide dismutase
MPG¼mercaptopropionylglycine
mPTP¼mitochondrial permeability transition
pore
MS¼metabolic syndrome
NAC¼N-acetylcysteine
NCE¼Na+/Ca2+ exchanger
NFjB¼nuclear factor jB
NHE¼Na+/H+ exchanger
nNOS¼neuronal nitric oxide synthase
NO ¼nitric oxide
NOS¼nitric oxide synthase
O2
- ¼ superoxide anion
OH ¼hydroxyl radical
OMM¼ outer mitochondrial membrane
ONOO-¼peroxynitrite
PCI¼percutaneous coronary intervention
PDH¼pyruvate dehydrogenase
PGC¼peroxisome proliferator-activated
receptor c coactivator
Pi¼ inorganic phosphate
PI3K¼phosphatidylinositol 3-kinase
PKA¼protein kinase A
PKB/Akt¼protein kinase B
PKC¼protein kinase C
PKG¼protein kinase G
PMA¼phorbol 12-myristate 13-acetate
PostC¼postconditioning
PPARs¼peroxisome proliferator-activated receptors
PreC¼preconditioning
PS¼phosphatidylserine
RIRR¼ROS-induced ROS release
RISKs¼ reperfusion injury salvage kinases
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
SAFE¼ survivor-activating factor enhancement
SNO¼ S-nitrosylation
STAT¼ signal transducer and activator
of transcription
STEMI¼ ST segment elevation myocardial
infarction
SWOP¼ second window of protection
TIGAR¼TP53-induced glycolysis and apoptosis
regulator
TNF¼ tumor necrosis factor
Tom20¼ outer membrane translocase 20
TSPO¼mitochondrial translocator protein
18kDa
UCPs¼uncoupling proteins
VDAC¼voltage-dependent anion channel
VO2¼ oxygen consumption
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